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Abstract  
Newborn babies can develop hypoxic-ischaemic encephalopathy (HIE) due to lack of 
blood supply or oxygen, resulting in a major cause of death and disability in term 
newborns. However, the current definitive treatment of therapeutic hypothermia, will 
only benefit one out of nine babies. Furthermore, the understanding of HIE and 
mechanisms of therapeutic hypothermia is not fully understood. Recently, microRNAs 
(miRNAs) have become of interest to many researchers due to its important roles in 
post-transcriptional control and deep evolutionary history. However, the role of miRNAs 
in newborns with HIE remains largely unknown due to limited research in this field. 
Therefore, this review aims to understand the role of miRNAs in normal brain 
development and HIE pathophysiology with reliance on extrapolated data from other 
diseases, ages and species due to limited data to date. This will provide us with an 
overview of how miRNAs in normal brain development changes after HIE. Furthermore, 
it will indicate how miRNAs are affected specifically or globally by the various 
pathophysiological events. For those that are interested in studying miRNAs, agents 
that can manipulate microRNAs are commercially available. In addition, we discuss 
about how drugs and agents can specifically target certain miRNAs as a mechanism of 
action and potential safety issue with off target effects. Improving our understanding of 
the role of miRNAs on the cellular response after HIE would enhance the success of 
effective diagnosis, prognosis, and treatment of newborns with HIE.  
 
Keywords: Newborns; hypoxic-ischemic encephalopathy; microRNAs; brain 
development; cellular death; neuroinflammation. 
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Introduction 
MicroRNAs (miRNAs) are evolutionary preserved short non-coding RNA molecules 
made up of 19 - 22 nucleotides, which are involved in the regulation of gene expression 
[1]. In central nervous system (CNS), miRNAs have been known to influence varying 
stages of neurodevelopment, including cell differentiation, proliferation and 
synaptogenesis [2]. Animal and human studies have shown that majority of miRNAs are 
expressed in brain tissue, in keeping with the complexity of nervous system and its 
connections [3]. The unique nature of miRNAs as potential biomarkers for a variety of 
diseases, including oncology [4], cardiovascular diseases [5], sepsis [6], and 
neurodegeneration [7], has been recently studied widely in adults and the pediatric 
population. However, the role of miRNAs in newborns with hypoxic-ischaemic 
encephalopathy (HIE) remains largely unknown.  
 
MiRNAs are known to be involved in normal brain development. As the newborn brain is 
still developing, it will be most likely that a number of miRNAs expression that are 
important in normal brain development are altered in conditions like HIE. Furthermore, 
animal studies of HIE have demonstrated that miRNAs can induce pathological changes 
in a variety of organs. Thus, miRNAs can be involved in the mechanism of hypoxic 
ischaemic injury itself, which could occur before, during and after the hypoxic insult. 
Furthermore, miRNAs could also be involved in the reparative process that happens 
after delivery of baby with or without the therapeutic hypothermia treatment.  
 
There are very limited studies on the role of miRNA in newborns under various 
physiological and pathophysiological conditions. As the miRNAs are evolutionally 
preserved, and the organs such as brain are still developing, it is likely that the 
expression of miRNA in newborns may be related to their counterparts in adults, but 
distinctive based on their regulatory role, . Furthermore, the limitation in the use of 
human fetal and neonatal tissue in research makes animal studies a useful alternative.  
 
In this article, we set out to review our knowledge on the roles of miRNAs relating to 
normal newborn brain development and then their roles in brain injury pathophysiology 
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from exploring published adult and animal studies. Furthermore, we will highlight known 
drugs and agents that could be used to alter the miRNA expression in future clinical 
research. This could pave way for future studies on specific miRNAs as a potential 
biomarker for brain injury in newborns and the development of novel therapeutic targets 
for perinatal asphyxia. 
 
Literature search 
The electronic database of PubMed was used to systematically search for relevant 
articles published between 1997 to 1st August 2018 by using a variety of search strings. 
To review the role of miRNAs in normal brain development, the searches involved the 
keyword miRNA and other keywords: ‘neural stem cells’, ‘neuronal migration’, ‘axonal 
and dendritic outgrowth’, ‘gliogenesis’, ‘synapse formation’, ‘biochemical changes’, 
‘myelination’, and ‘vascular development’. To review the role of miRNAs in brain injury, 
the keywords: ‘miRNA and neuronal cell death’, and ‘miRNA and neuroinflammation’ 
were chosen. ‘MicroRNA and neonatal encephalopathy’, ‘microRNA and hypoxic-
ischaemic encephalopathy’, ‘miRNA and therapeutic hypothermia/cooling’, ‘microRNA 
and neonatal hypoxia’, ‘microRNA and neonatal brain ischaemia’, ‘microRNA and 
neonates / babies’, and ‘microRNA and neonatal brain’ revealed 32 studies. These 
miRNAs have been discussed in detail later in the HIE pathophysiology section. Due to 
limited studies in neonates, relevant miRNAs associated with brain injury involving older 
children, adults, animals or in-vitro cell cultures were also highlighted in the review. 
 
 
MiRNAs in newborn brain development 
Newborn human brain development commences from first few weeks of gestation and 
continues well beyond the first 2 years of life and into early childhood with ongoing 
myelination and synaptogenesis. In addition, other major cellular developmental 
changes in newborn human brain including cell proliferation, neuronal migration, 
synaptogenesis, synaptic pruning, myelination and connectivity, and immunological 
changes have been well documented [8]. We aim to detail a complete review of 
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miRNAs in newborn human brain development using available and extrapolated 
knowledge on miRNA changes noted in animal in vitro and in-vivo studies. 
 
Neurogenesis and gliogenesis 
Neurons and glial cells including astrocytes and oligodendrocytes are formed from the 
multipotent self-renewing neural stem cells (NSC). Neurogenesis occurs predominantly 
in early embryonic stage in the ventricular zone and continues until early postnatal life 
with very little ongoing adult neurogenesis from the quiescent NSCs [9]. A few known 
miRNAs such as miR-9, miR-25 /106b-25 cluster and miR-134 play a role in enhancing 
NSC proliferation, but a few others such as Let7b, miR-128 and miR-506 could inhibit 
NSC proliferation (Figure 1). Several intracellular pathways are involved, including the 
Notch/Hes signaling with miR-9 to enhance NSC proliferation [10]. Alternatively, 
overexpression of Let7b reduces NSC proliferation via TLX and cyclin D pathway [11]. 
Interestingly, perinatal hypoxic-ischaemic injury induces proliferation of NSC in sub-
ventricular zone, possibly as a reparative mechanism as progenitor cells are susceptible 
to this form of injury [12-14].  
 
Distinctively, gliogenesis starts in 2nd trimester and continues until a couple of years of 
age. In addition to being supportive cells to neurons, glial cells also play a vital role in 
neurogenesis by influencing neuronal migration, formation of blood-brain barrier and 
regulation of myelination. In CNS, oligodendrocytes are produced from the 
oligodendrocyte progenitor cells (OPC) with immature oligodendrocytes peaking around 
28 to 40 weeks of gestation. There is a complex network of miRNAs involved in OPC 
development either alone or in combination through a number of pathways as shown in 
(Figure 1). For example, increase in OPC miR-219 and miR-338 can promote their 
differentiation into myelinating oligodendrocytes by repressing their target genes of 
platelet-derived growth factor receptor  (PDGFR), Sox6, FoxJ3, and ZFP238 proteins 
[15, 16]. OPCs are particularly vulnerable to perinatal hypoxic-ischaemic injury, leading 
to permanent white matter damage [17].
 
This hypoxic injury also promotes proliferation 
of sub-populations of NG2 positive neural progenitor cells, which may differentiate into 
myelinating oligodendrocytes [17, 18].
 
Since this developmental process is 
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predominantly ongoing in the 3rd trimester, it is most likely to be interrupted in newborns 
during hypoxic-ischaemic injury. Moreover, the switch between neurogenesis and 
gliogenesis has been suggested to be strongly influenced by miRNAs, including 
miR17/106 based on the timing of the developmental process and complex interaction 
between various pathways [19, 20]. 
 
Neuronal migration, maturation and connectivity 
Neuronal migration is an important step following the proliferation and differentiation of 
precursor neuronal cells, as it helps to bring various types of cells together to their final 
location. In CNS, this process is supported by radial glial cells. A variety of miRNAs has 
been shown to be involved in promoting radial migration of neurons and axons through 
a number of pathways (Figure 1). Inhibition of a brain enriched microRNA such as miR-
9 have shown to increase axonal length and reduce axonal branching in culture neurons 
[21]. Other neuronal processes such as dendritic growth, dendritic spine formation, and 
development of dendritic complexity as also influenced by miRNAs (Figure 1). As 
dendrites are the site of most synaptic contacts, adequate growth and branching of 
dendrites are important for healthy neural circuitry function. Similarly, investigation of 
miRNAs for their role in synaptic process have been carried out. A few miRNAs 
including miR-9, miR-124, and miR-132 have been shown to consistently promote 
synaptogenesis, while miR-125, miR-134 and miR-137 exhibit opposing affects (Figure 
1). The structural and functional synaptic plasticity is an important and highly regulated 
process that is necessary to maintain normal function and repair of nervous system. 
Numerous miRNAs involved in this process are concentrated in both pre- and post-
synaptic junctions, which has been summarised in a few reviews [22-24]. Furthermore, 
various miRNAs are also altered in the mechanism of long term potentiation which 
forms the basis for cognition and memory [25]. Thus, miRNAs are not only involved in 
synaptic protein synthesis, but also in the formation and maturity of the synapses, which 
are important for learning and memory.  
 
Myelination 
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Oligodendrocytes in CNS provide the primarily source of myelin sheaths, which is 
important for axonal insulation to enhance conduction speed of action potentials. 
Currently, two miRNAs have been implemented with myelination, namely miR23a and 
miR219 (Figure 1). In particular, miR-23a has been previously shown to suppress 
laminB1 via the PTEN/PI3K/AKT pathway to enhance oligodendrocyte differentiation 
[26]. 
 
Vascular development 
Angiogenesis involving sprouting of new capillaries and neurogenesis are both crucial 
processes for brain tissue repair and remodeling after brain injury.
 
The blood brain 
barrier (BBB) is a specialised non-permeable barrier in cerebral microvessels, formed 
primarily by endothelial cells united through tight junctions with astrocytic end feet 
surrounding the blood vessels, and pericytes embedded in the vascular basement 
membranes. In addition, microglia and neurons have essential roles in CNS 
homeostasis in the form of the neurovascular unit [27]. Several miRNAs are involved in 
angiogenesis and BBB formation and disruption (Figure 1). For example, miR29b have 
been hypothesised to regulate BBB dysfunction via the enzymes MMP9 and DNMT3b 
[28]. 
 
Summary of role of miRNA in healthy brain development 
There are many organ specific miRNAs, but a significant proportion are expressed in 
brain [29]. This signifies their importance and complexity of evolution, and their role in 
neural development. MiRNAs expression can be varied with temporal and spatial 
differences relating to developmental stages and anatomical areas of the CNS [30]. 
Therefore, miRNAs can be expressed differently in neuronal precursors and stem cells 
through the various stages of differentiation to mature neurons [31]. Furthermore, they 
can have dual action due to its presence in one cell type to suppress expression and to 
be absent from another cell at another time point to allow for genetic expression. 
Moreover, miRNAs can not only be present within cells, but can also circulate freely 
extracellularly within exosomes, and act on other distant cells. For example, miR-21 and 
miR-29a can act as a ligand on TLR receptors to induce an inflammatory response [32]. 
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With this knowledge of the complex activities of miRNAs, the roles of miRNA in various 
stages of HIE are further discussed.  
 
Hypoxic-ischaemic encephalopathy 
Neonates can be affected by varying degrees of perinatal asphyxia, due to lack of blood 
supply or oxygen in peripartum period. Those affected by perinatal asphyxia can 
develop a clinical condition called hypoxic-ischaemic encephalopathy (HIE). It is a major 
cause of death and disability in term newborns, which affects around 2-3 per 1000 live 
births in developed countries [33]. HIE is not a specific diagnosis but a constellation of 
clinical features of encephalopathy related to various aetiologies resulting in perinatal 
asphyxia. Currently, the standard of treatment is to offer therapeutic hypothermia 
between 33 – 34oC for a 72 h period to babies with moderate to severe HIE based on a 
selected clinical criteria [34]. With the current clinical guidelines to select the babies for 
therapeutic hypothermia, the numbers needed to treat is nine to prevent one additional 
baby with severe disability or death [35]. This is because of the complex etiologies 
leading to the clinical presentation and lack of robust biological markers to assist in 
identification and selection of all babies potentially affected by perinatal asphyxia to 
initiate therapeutic hypothermia early.  Recently, clinical studies have been conducted 
to identify other neuroprotective or restorative therapies as standalone or adjuncts to 
therapeutic hypothermia to improve the outcome for HIE babies [36].  
 
MicroRNAs associated with HIE pathophysiology  
To date, there are only a couple of published studies studying the expression of miRNA 
in human neonatal HIE [37, 38]. In a small cohort of babies with HIE, Chen has 
selectively studied the expression of miRNA-21 and HIF-1α and found them be higher in 
serum in HIE babies compared to normal controls [37]. In a methodology paper on use 
of dried blood spots to extract miRNAs, we have previously studied selected miRNAs 
(Let7b, miR-21, miR-29b, miR-124 and miR-155) and did not find their expression 
significant in HIE babies [38]. However none of these studies have identified the 
mechanism of action of relevant miRNAs. Other closely-related studies include those on 
umbilical cord blood [39-41] and maternal blood [42]. Looney and colleagues have 
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shown that microRNA miR-374a is downregulated in the umbilical cord blood of infants 
with HIE and suggested a possible pathway for miR-374a involving activin-A through its 
receptor AVCR2B [39]. Subsequently, Wang et al has selectively studied miR-210 and 
miR-374a also in umbilical cord blood and shown its combined potential role as 
biomarker for severity and prognosis of HIE[41]. A study on maternal blood has shown 
miR-20b and miR-21 to be related to fetal hypoxia during labour [42]. The remaining 
published studies vary from in-vivo rat and piglet animal models to cell cultures under 
various hypoxic-ischaemic conditions. In rat primary hippocampal neuronal cultures. Cai 
and his colleagues show that miR-27a overexpression attenuates hypoxia- and 
ischemia-induced neuronal apoptosis by regulating FOXO1 [43]. Similarly, in both in 
vitro and in-vivo studies, hypoxia induced expression of miR-152 in rats has been 
shown to suppress cell apoptosis and acts as a protective factor during by repressing 
PTEN [44]. Other studies on in-vitro cultures has shown upregulation of miR-210 to be 
neuroprotective through its effects on apoptotic proteins [45] and downregulation of 
miR-139-5p to be also neuroprotective through activation of Human growth 
transformation dependent protein [46]. However, a microarray on rat cerebral cortex 
highlight other miRNA’s including mir-429, mir-200b, and mir-182 to be significant in HIE 
animal model [47], while in another study of microarray of neural tissues a different miR-
199a has been shown to be significant [48]. 
 
Likewise, studies on piglet model of HIE has shown  temporal changes in miRNA 
expression  in mir-23a-5p, mir-27a-5p and mir-31-5p to be useful potential biomarkers 
to distinguish between hypoxia and infection-sensitised hypoxia [49], and miR-374a and 
miR-210 to be important regulators in neonatal HIE [50]. Moreover, therapeutic 
hypothermia, which is now a standard treatment for HIE has also been shown to cause 
changes in miR-874 and miR-451 in adult rats with traumatic brain injury [51]. Overall, 
these studies have been varied in methodology and have shown changes in various 
miRNA in HIE. 
 
None of the above studies have highlighted any specific miRNA to be a reliable and 
reproducible biomarker or therapeutic target in HIE in neonates. Since we currently 
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know little about miRNA expression in neonates with HIE, reliance on well-researched 
diseases such as cancer is necessary. MiRNAs have been successfully shown to 
influence various pathophysiological changes in these diseases which have much 
similarities with HIE. As a starting point, this review will extrapolate miRNA expression 
data from studies that exhibit similar pathological changes as observed in HIE at the 
cellular level. Although some microRNA targets have been suggested, it is most likely 
that there are other miRNAs involved in the HIE pathophysiology that are unexplored, 
due to lack of knowledge and understanding of miRNAs in HIE.  
 
MiRNAs in hypoxic-ischaemic pathophysiology 
In simplified terms, two major pathological changes occur in HIE, which include various 
forms of neuronal cell death involving necrosis, apoptosis, autophagy, excitotoxicity, 
and axonal degeneration, which is then followed by neuroinflammation triggered 
through central and peripheral immune cells. This review will explore the role of miRNAs 
in neuronal death and neuroinflammation obtained from adult human and animal 
studies, in order to further elucidate the role of miRNAs in newborns with HIE.  
 
Neuronal Cell Death  
The initial phase of primary energy failure in HIE results in the first wave of cell death 
[52]. Although necrosis is the commonest form of neuronal death, other forms of 
neuronal death such as apoptosis, autophagy and excitotoxicity have been noted in 
animal models of HIE [53, 54].  
 
Necrosis is initiated due to lack of energy or direct injury to cell membrane. A number of 
mediators including mitochondrial, lysosomal, nuclear, cytosolic or cell membrane 
related changes could potentiate the injury. MiRNAs such as miR-19b, miR-21 and miR-
23a have found to be involved in necrotic cell death (Figure 2).  In a transgenic murine 
model, miR-23a has been shown to control mitochondrial permeability by targeting 
peptidylprolyl isomerase F (PPIF), which restricts reactive oxygen species (ROS) flux 
[55]. In rodent in vitro and in vivo models, miR-21, miR-874 and miR-2861 have been 
shown to regulate necrosis/necroptosis through complex interaction and disruption of 
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various protein complexes namely receptor interacting protein 1 and 3 (RIP1/RIP3) [56] 
or mitochondrial nucleotide transporter, adenine nucleotide translocase 1 (MNTANT-1) 
[57]. Additionally, many miRNAs involved in necrosis are also involved in inflammatory 
conditions. Secondary inflammatory response following the release of intracellular 
contents could be initiated by necrosis [58]. Interestingly, miR-351 has been reported to 
switch cell death process between necrosis and apoptosis in rodent cell lines [59].  
 
Apoptosis occurs when the cells undergo certain specific changes, including chromatin 
condensation, nuclear fragmentation and blebbing of intact plasma membrane to form 
apoptotic bodies [60]. Eventually, these apoptotic bodies are engulfed by phagocytes 
with no associated inflammatory reaction [61]. A large variety of miRNAs is now known 
to be involved in apoptotic death across various tissue types [62-65] (Figure 2). Studies 
on CNS-related miRNAs, come mostly from rodent model or cell lines involving 
neuroblastoma, glioblastoma, neuronal or retinal ganglion cells. For example, elevated 
expression of miR-17-5P-92 cluster can inhibit p21 and BIM translation, which leads to 
activation of apoptosis in neuroblastoma [66]. Another well-studied miRNA is miR-21, 
which has been shown to exhibit several roles in apoptosis. Although the role of 
miRNAs and apoptosis is more studied that necrosis, the exact mechanisms of miRNAs 
in the involvement in apoptosis remain to be determined.  
 
Autophagy is another form of cell death when there is vacuolisation of the cytoplasm 
within the cell, which causes the cell to degrade their organelles and cytoplasm through 
the lysosomal system, involving Ras, beclin-1, mammalian target of rapamycin (mTOR), 
and phosphatidylinositol 3 (PI3)-kinase signaling pathways  [67, 68]. A variety of 
miRNAs is known to be involved in autophagy (Figure 2). For example, the mTOR 
signaling pathway can be repressed by Let-7 in primary P0 cortical mouse neurons [69] 
or increased by miR-155 in human cancer cell lines [70]. In an ovarian endometriotic 
cell line, the beclin-1 signalling pathway have been associated with miR-210 [71]. 
Overall, the process of autophagy has been shown to be either a pro-survivor of cells or 
promotor of cell destruction in neonatal HIE models based on injury severity, timing of 
insult, and brain region involved [54].  
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Excitotoxic neurodegeneration is a type of neuronal cell death due to activation of 
glutamate-gated ion channel receptors causing activation of calcium sensitive 
proteases, protein kinases/phosphatases, phospholipases, and nitric oxide synthase 
(NOS) [54]. This results in intracellular changes similar to both necrosis and apoptosis 
especially in immature brain indicating a continuum between the various models of cell 
death [72]. Some of the miRNAs including miR-19, miR-21 and miR-223 are involved in 
excitotoxicity (Figure 2). For example, overexpression of miR-223 can lower the levels 
of GluR2 and NR2B subunits of glutamate receptor, resulting in the inhibition of NMDA-
induced influx in hippocampal neurons [73].  
 
Axonal degeneration has been well studied in neurodegenerative and traumatic injury 
animal models, but relatively unheard of in HIE. Since neuronal cells in grey matter are 
metabolically more active compared to white matter, the direct injury to axons and glial 
cells is not often observed in hypoxic-ischaemic injury. However, studies have shown 
that axonal degeneration induced by hypoxia can been observed in nematode C. 
elegans through induction of HIF-1 [74], and in adult mouse brain through AMPA/kinase 
receptor activation [75]. It is likely that chronic hypoxia plays a role in axonal 
degeneration either directly or through triggering inflammatory pathways, but it is not 
considered a type of cell death, since the neuronal body is often still alive following 
axonal degeneration. While certain miRNAs, including miR-34, miR-410, miR-431 are 
found to influence axonal degeneration in spinal cord and peripheral nerves [76], not 
much is known about role of miRNAs in axonal damage and repair in CNS relating to 
hypoxia and ischaemia. 
 
Summary of neuronal cell death 
Thus, neuronal cell death could follow any of the above modes of neuronal death or 
injury involving a number of pathways. There is definite cross-linking and signalling 
between these pathways based on severity and type of injury, which are linked to a 
number of miRNAs involved in all these processes. Although our understanding of 
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miRNAs is increasing, we are far from unveiling the mystery of the role of miRNAs in 
many pathologies of neuronal death in neonatal HIE. 
 
Neuroinflammation 
Following initial phase of neuronal cell death by necrosis, the release of inflammatory 
mediators outside the cells induces further secondary neuronal damage by a number of 
inflammatory cells from both central and peripheral immune system. Although the role of 
inflammatory cells is predominantly to remove debris and dying neurons through 
phagocytosis, they can also cause death of healthy neighbouring neurons through 
excitotoxicity, microglial activation and apoptosis. This secondary neuronal death 
process can take a few hours to weeks. As demonstrated in oncology, miRNAs have 
also been well studied in neuroinflammatory conditions leading to neurodegeneration 
like multiple sclerosis [77], Alzheimer’s disease and Parkinson’s disease [78]. 
Furthermore, miRNAs have been suggested to fine tune inflammation through 
alterations in immune cell differentiation and function via circulating in extracellular 
vesicles to communicate between neurons and immune cells [78]. Role of various 
immune cells in neuroinflammation and their interaction with miRNAs are explored 
further. 
 
Central inflammatory cell response 
Microglia 
Microglia are the resident immune cells in the brain, which act as a gate keeper for 
inflammation through constant surveillance of the CNS microenvironment using their 
long thin ramified processes. However, once activated they retract their processes to 
express an amoeboid phenotype and migrate immediately to the area of injury, 
especially in developing brain. In the activate form, microglia can express a pro- or anti-
inflammatory role. The pro-inflammatory pathway is mediated by Th1 type cytokines like 
IFN-γ or TLR agonists resulting in inflammatory tissue damage through release of pro-
inflammatory cytokines including IL-6, TNF-α and NO [79]. Alternatively, microglia can 
take on an anti-inflammatory phenotype through alternate activation by Th2 type 
cytokines including IL -4 or IL-13 [79]. The anti-inflammatory role involves the clearing of 
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debris and ROS, and release neurotrophic factors with an ultimate aim to promote 
neuronal repair and recovery. Moreover, microglia can switch between the 2 
phenotypes based on the timing and type of inflammatory signaling, resulting in a wide 
spectrum of intermediate phenotypes [80]. Interestingly, microglial activation can also 
recruit other peripheral immune cells including monocytes, macrophages, neutrophils 
and T-lymphocytes through chemokine release [81].  
 
The role of miRNAs in development and activation of microglia has been previously 
reviewed by Ponomarev and colleagues [79]. In summary from various studies on 
mouse microglial cells, there are a number of miRNAs known so far to promote an anti-
inflammatory phenotype via a variety of pathways (Figure 3). For example, Let-7a have 
been shown to reduce NO and IL-6 [82]. Another example is miR-124, which can act 
through C/EBP-α–PU.1 pathway [83], or targeting a key mediator of NLRP3 
inflammasome, nfkB-regulator ikBzeta and Irf1 [84], or through peroxisome proliferator-
activated receptor-gamma pathway [85]. On the other hand, miRNAs including miR-101 
via MAPK phosphatase-1 pathway, and miR-155 via anti-inflammatory genes have 
shown to promote microglia induced an inflammatory response [79]. Interestingly, some 
miRNAs namely miR-146 and miR-21 control and resolve inflammation through 
negative feedback signalling [79]. In addition to these miRNAs highlighted in the review 
by Ponomarev and colleagues, a number of other miRNAs have also been shown to be 
involved in microglial activation as shown in figure 3. While we understand the extent to 
which certain miRNAs can activate and regulate microglia induced injury in hypoxic-
ischaemic conditions, it is unclear whether additional miRNAs are involved and/or if 
these expressions hold true in newborns with HIE.  
 
Astrocytes 
Astrocytes are the most abundant glial cells in CNS and under normal conditions, 
contribute to limiting inflammatory responses by formation of glial limitants [86, 87]. 
However, these glial cells play an important role in brain development, plasticity and 
homeostasis [88]. In various animal models of HIE, reactive astrogliosis is noted 
following hypoxic injury, which sets off a cascade of inflammation through release of 
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inflammatory cytokines (IL-1, IL-6, TNF-α, and IFN-) and chemokines [81]. Similarly to 
microglia, astrocytes can also express an anti-inflammatory role through release of 
glutathione and superoxide dismutase, and enhancing extra-synaptic glutamate uptake 
and induction of brain derived neurotrophic factor (BDNF), thus protecting neurons by a 
number of mechanisms [81]. Ouyang and colleagues have summarised in detail studies 
on some of the brain enriched miRNAs, namely miR-181 and miR-29 families and miR-
146a as they have been found to be highly expressed in astrocytes and noted to have 
both pro-and anti-inflammatory roles depending on the targets and the cells of 
expression [88]. The expression of these miRNAs differs greatly based on the brain 
region and gestation age as demonstrated with human adult and fetal brain tissues [89]. 
Other miRNAs that involve astrocytes are shown in Figure 3. For example, miR-7 can 
decrease endoplasmic reticulum (ER) stress protein-HERP2 in primary cultured mouse 
astrocyte [90]. In primary P1 astrocyte culture model of ischemia-reperfusion injury, 
miR-29a can target the pro-apoptotic BCL2 family member PUMA [91]. These miRNAs 
and its associated pathway exhibit a neuroprotective role. Paradoxically, miR-34b can 
repress Bcl-2 resulting in hippocampal astrocyte apoptosis [92]. In addition, miR-155 
have shown to target suppressor of cytokine signaling 1 in cell culture using human fetal 
tissue [93]. These miRNAs and its associated pathway can worsen the injury through 
the pro-inflammatory role. Additionally, miR-124a transported as exosomes has also 
shown to provide an astrocyte-neuron connection [94], thus promising a potential role 
for astrocytes and its miRNAs in neuroprotection. Therefore, in relation to the pathways 
the astrocytic miRNAs are involved, it suggests they have a close relationship to 
neuronal function and structure. 
 
Peripheral inflammatory cell response 
Neutrophils  
Neutrophils are the most abundant circulating white cells and are the first peripheral 
inflammatory cell type recruited at both acute and chronic inflammation. Various animal 
studies have shown infiltration of neutrophils in ischaemic areas of adult brain within 
hours of insult, while in neonatal models of hypoxic ischaemic injury, the neutrophil 
response in brain is often diminished, as they seem to stay predominantly intravascular 
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[81]. Neutrophils help to combat tissue injury by phagocytosis and releasing toxic 
granulations to destroy the pathogens. However, additional tissue injury can occur 
through ROS, cascading further inflammation via recruitment of macrophages and its 
release of cytokines to activate T-helper cells [95]. To date, the role of only few specific 
miRNAs; namely miR-142, miR-223, miR-451 and miR-446I relating to inflammatory 
role of neutrophils have been summarised [95](Figure 3). MiR-223 is one neutrophil-
related miRNA that has been predominantly studied, which is found to be a negative 
regulator of granulocyte differentiation and involved in fine tuning neutrophil function 
[96]. Some of the confirmed targets and modes of action for miR-223 involve targeting 
C/EBPα and NFI-A [97], NLRP3 [98], suppressing neutrophil infiltration and ROS 
production [99], or Mef2c, a transcription factor that promotes myeloid progenitor 
proliferation [100]. However, due to limited studies, the exact role of neutrophils and 
their expression of miRNAs in HIE of a term human neonate still remains a mystery.  
 
Monocytes/Macrophages 
Monocytes/macrophages are also part of innate immunity through their phagocytic 
actions. However, there is currently no clear study to explain their role in HIE 
pathogenesis although several miRNAs are associated with monocyte/macrophage 
(Figure 3). Stimulation of monocytic cells by the bacterial endotoxin lipopolysaccharide 
(LPS) has shown up-regulation of miR-9 [101], miR-21 [102, 103], and miR-146a [104] 
all through Nuclear factor-κB pathway. The target of miR-155 has shown to be through 
enhancing TNF- translation [105, 106], and JNK pathway [107]. Furthermore, LPS 
stimulation can cause positive regulation of let-7e and miR-181c, but negative 
regulation of miR-155 and miR-125b through protein kinase Akt1 [108]. Overall, certain 
myeloid derived miRNAs mentioned above have been shown to be involved in LPS-
induced inflammation via in vitro studies. As HIE could be a triggered by infection, these 
miRNAs could play a role in the initiation of cellular injury through primary inflammation. 
 
Dendritic cells 
Dendritic cells are antigen-presenting cells that play important roles in linking innate and 
adaptive immune responses. Various types of dendritic cells have been noted in human 
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and mouse studies including classic or conventional, Langerhans, plasmacytoid and 
monocyte-derived dendritic cells [109]. Immature dendritic cells produced from 
haematopoietic stem cells mature on stimulation by toxins. A number of miRNAs 
involved in other pathophysiological processes in HIE such as Let-7 family, miR-155, 
miR-223 and miR-29 family, have been shown to be expressed during the process of 
differentiation and maturation of dendritic cells [109]. Some of the well studied miRNAs 
involving dendritic cell activation are highlighted in Figure 3.These miRNAs have been 
noted to either positively or negatively regulate the ability of dendritic cells in processing 
antigens. Smyth and colleagues describe in detail certain miRNAs are involved in 
various roles relating to dendritic cells maturation and function [109]. As a vital cell in 
triggering antigen specific immune response, it is likely that these dendritic cells play a 
role in inflammation relating to HIE.  
 
T-lymphocytes 
T-lymphocytes, which are derived from thymocytes are differentiated from 
haematopoietic stem cells and have a major role in cell mediated immunity. In vitro and 
in vivo studies have shown a small number of miRNAs, including miR-142a, miR-146a, 
miR-155 and miR181a are capable of influencing the function of T-lymphocyte mediated 
through other inflammatory cells (Figure 3). In particular, miR-155 has been found to be 
highly related to T-lymphocyte development, as a number of studies have found its role 
in differentiation of T-helper cell [110], T-regulatory cells [111], T-cell dependent 
inflammation [110], and for effective function of T- and B-lymphocytes and dendritic 
cells [112]. MiR-181a expression has been shown to play a key role in maturation of T-
lymphocytes through positive selection [113]. The direct role of T-lymphocytes in 
hypoxia-related inflammatory process is unclear. However, it has been noted that 
newborns have an equally efficient, although different T-cell immunity response 
compared to adults [114]. Additionally, unlike adults, neonates have been shown to 
express CXCL8-producing T-lymphocytes in response to inflammation, very early on 
even though their immune system is limited in mounting T-helper type 1 cell response to 
bacteria and virus [115]. These differences between adult and newborns may suggest 
that adult and neonatal inflammatory process involve different miRNAs.  
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B-lymphocytes 
B-lymphocytes provide humoral immunity through their antibodies and are activated 
either as T-cell dependent or independent activation depending on the antigen type. A 
number of miRNAs can regulate B-cell lymphopoiesis and maturation including miR-23a 
[116], miR-34a [117], and miR-212/132 cluster [118]. Rodent studies have shown that 
certain well studied miRNAs like miR-155 [119] and miR-181 [120, 121] have also been 
noted to be involved in the functional aspect of B-lymphocytes influencing their antibody 
response, in addition to their effect on other inflammatory cells. Figure 3 summarises 
various other miRNAs involved in B-lymphocytic activation. However, very little is known 
on B-lymphocytes role and function in hypoxic and ischaemic conditions, even in animal 
studies to extrapolate to pathogenesis of HIE in neonates.  
 
Summary of neuroinflammation 
Some miRNAs such as miR-223, miR-142, miR-146, let-7 family and miR-155 are well 
known to be involved directly or indirectly in the inflammatory cascade through a 
number of immune-related cells. While the primary pathology in HIE is cellular death 
followed by secondary inflammation, the etiology of HIE is often unclear. As described 
earlier, HIE is currently a diagnosis based on clinical criteria and often causes other 
than pure hypoxia and ischaemia at birth could mimic as HIE. The most common 
confounding factor in the etiology of HIE is sepsis and LPS-related injury. These 
pathological events could thus be a primary cause for hypoxia and ischaemia in 
perinatal period triggering neuroinflammatory pathways ahead of cellular death.  
 
While there is lack of studies on role of specific cells in HIE in human neonate, 
understanding the targets and pathways of some of the well-studied miRNAs and their 
role at cellular level in a variety of inflammatory conditions would be useful to 
extrapolate for unknown conditions like HIE. 
 
MicroRNA in therapeutic hypothermia 
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It has been suggested that therapeutic hypothermia being the established treatment 
modality for HIE works through a number of mechanisms, including reduction in 
apoptosis, excitotoxicity, and neuroinflammation [122]. Studies on miRNAs in 
hypothermia have shown that hypothermia can reduce the expression of miR-122 in 
adult porcine cardiogenic shock model [123], and increase miR-155 expression in 
primary cultured adult human monocytes exposed to 32 °C [124]. Interestingly, in vitro 
studies on neuronal cell lines have shown that cold shock protein RBM3 can contribute 
to therapeutic effects of hypothermia through regulation of protein synthesis [125]. 
Additionally, another RNA binding protein Lin-28 has also been shown to significantly 
regulate early embryonic development and differentiation by blocking the biogenesis of 
let-7 family through their cold shock domain [126]. While therapeutic hypothermia is well 
studied in preclinical studies, the exact mechanism of how it provides clinical benefit in 
neonatal HIE remains unclear [127]. The understanding of miRNAs in newborns with 
HIE could add more information to our current understanding of pathological changes in 
HIE at the genetic and cellular level.  
 
Modulating microRNA with pharmacological agents 
Understanding the role of microRNAs in different pathological events has shown that in 
addition to being a biomarker, they can also be potential therapeutic targets. 
Researchers have been able to successfully mimic endogenous miRNA or decrease 
miRNA expression in vitro and in vivo using commercially available pharmacological 
agents (Table 1). It should be noted that in RNA interference, miRNA inhibitors should 
not be mistaken with small interfering RNAs (siRNAs), since miRNA inhibitors can have 
multiple mRNA targets and siRNAs are specific to one mRNA target [128]. The delivery 
methods can be used directly in buffer [129], or with transfection reagent such as 
lipofectamine [130], or plasmid-based [131], or viral vector-based systems [132]. 
 
Recently, medications used in clinics have been shown to alter miRNA expression as a 
mechanism of action (Table 2). For example, nicorandil, an anti-angina drug can 
upregulate miR-7 to induce an anti-inflammatory effect in primary cultured astrocytes 
induced by oxygen-glucose deprivation [90]. Pioglitazone, a peroxisome proliferator-
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activated receptor (PPAR)- agonist used to treat type 2 diabetes can downregulate 
miR-29 resulting in increased cell survival and decreased caspase 3 activity in a model 
of ischaemia-reperfusion injury [133]. The anti-cancer drug, bleomycin, acting through 
inhibition of PDGF-B and TGF signaling pathways can reduce miR-29 expression in a 
model of systemic sclerosis [134]. Furthermore, treatment with an anti-cancer drug, 
imatinib can restore the levels of miR-29a-c in vitro and in the bleomycin model in vivo 
[134]. MiR-9 level was decreased by erlotinib, an EGFR inhibitor used to treat non-small 
cell lung cancer [135]. Valproic acid, an anti-convulsant drug can induce miR-124 to 
repress guanine nucleotide binding protein alpha inhibitor 1 (GNAI1) [136]. 
Natalizumab, a humanized monoclonal antibody that is used to treat relapsing-remitting 
multiple sclerosis has been shown to down-regulate miR-155 and miR-26a in blood of 
multiple sclerosis patients [137]. Metformin, an anti-diabetic drug used to treat type 2 
diabetes can down regulate miR-21 an affecting the PI3K/AKT pathway [138]. 
Moreover, the anti-fibrosis drug bortezomib restore the miR-21 expression increase in 
bleomycin-induced skin fibrosis [139]. The pan-deacetylase inhibitor panobinostat used 
to treat various types of cancer can promote the maturation of let-7b, which inhibit 
HMGA2 expression [140]. Interestingly, chemical agents present in our diet can also 
alter miRNA expression (Table 2). Curcumin, which is present in turmeric and curry, has 
been demonstrated to suppress colon cancer proliferation via the down-regulation of 
miR-130a by inhibiting Wnt/-catenin pathways [141]. Epigallocatechin-3-O-gallate, 
which is present in green tea can up-regulate let-7b causing a down regulation of 
HMGA2 [142]. Finally, iIsoliquiritigenin, which is present in licorice can inhibit miR-25 
and trigger autophagy by increasing ULK1 expression [143]. 
 
Potential safety issues in modulating miRNAs during development 
Although modulation of miRNAs can be beneficial as previously discussed in the review, 
it can also give rise to potential safety issues, especially when miRNAs can affect 
multiple mRNA targets. Since miRNAs can potentially target around 200 genes, any 
agent aimed to alter a specific miRNA expression could result in off-target effects [144]. 
For example, miR-155 is involved in autophagy and necrosis, and in neuroinflammation. 
Furthermore, miR-155 is associated with microglia/macrophages, astrocytes, and 
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dendritic cells. Therefore, if targeting miR-155 for autophagy and necrosis, it would also 
affect neuroinflammation, which the process currently remains inconclusive if beneficial 
or detrimental [145, 146]. Another example is miR-124, which can promote neuronal 
differentiation via SCP1 or SOX9, inhibit synaptic activity via CREB1, promote neurite 
outgrowth and neuronal migration via FOXP2, and promote microglia quiescence via 
C/EBP –alpha-PU.1 pathway [83, 147]. Therefore, it is unknown what will be the overall 
consequence of altering global brain miR-124 levels has on the unintended pathways 
for neuronal differentiation, synaptic activity, axonal growth and the innate 
neuroinflammation. MiRNA can also post-transcriptionally regulate extremely important 
enzymes, in particularly the cytochrome P450 superfamily, which are involved in the 
both the catalysing and the activation of agents [148]. In such cases, the off target can 
be detrimental for the newborn. For example, CYP1B1 has been associated with cancer 
and is negatively regulated by miR-27b, so an increase in CYP1B1 may lead to 
carcinogenesis from reducing miR-27b expression [149]. Overall, the use of In Silico 
programs would minimise any detrimental off target effects. However, since our current 
knowledge of miRNA and its effects remains limited, further research in miRNA will help 
us understand better the biology of miRNAs in normal and disease states in newborns.  
 
Conclusion 
This review has focused on known changes at cellular level both in the developmental 
brain physiology and pathophysiology observed in HIE. However, since there are limited 
data on miRNAs that associate neonates with HIE, this review could only extrapolate 
from non-neonates and other diseases such as cancer, cardiovascular and 
neuroinflammatory conditions present in adults. From our understanding of miRNAs, it 
is likely that the miRNA changes observed in these cellular processes would reflect 
similar changes in neonates with HIE, since most plants and animal miRNAs are 
evolutionally conserved as they are vital in gene regulation. As we have discussed in 
the review, miRNA expression and their regulatory functions are complex mechanisms 
that requires further studies to fully appreciate role of miRNAs in newborns with HIE. 
However, the successful could pave way to develop better biomarkers of brain injury 
and be sought for effective neuroprotective treatments.  
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Figure legends 
Figure 1. MiRNAs involvement in normal neonatal brain development. A variety of 
processes that occur during brain development are involved with miRNA, including cell 
division (proliferation, gliogenesis), neuronal changes (differentiation, migration, 
synaptogenesis, axonal and dendritic outgrowth, and myelination), and vasculature 
changes (blood brain barrier and angiogenesis).  MiRNAs highlighted in blue and red 
colour indicate an up regulatory and down regulatory role, respectively. References are in 
italics next to each miRNA in brackets. Superscript letter(s) with reference denotes source 
of data: a, rodent cell culture; b, immature rodent; c, adult rodent; d, zebrafish; e, Drosophila; 
f, C. elegans; g, Aplysia; , human cell culture; , immature human; , adult human. 
 
Figure 2. MiRNAs in cellular death. Cell death can be classified into excitotoxicity, 
autophagy, necrosis and apoptosis. References are in italics next to the miRNAs in 
brackets.
Figure 3. MiRNAs in neuroinflammation. Neuroinflammation can be of CNS origin, which 
involve microglia, astrocytes, and microglia-derived macrophage. Alternatively, 
neuroinflammation can be of PNS origin, which includes monocytes derived macrophages, 
neutrophils, dendritic cells, T- and B-lymphocytes. References are provided next to the 
miRNAs in figure and in the legend below. 
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Figure 1 
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Figure 2 
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Figure 3 
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Table 1. Commercially available pharmacological agents that can mimic or inhibit miRNA 
response. Depending on the company, the terminology for miRNA mimics and inhibitors 
can exist in alternative names. 
 MiRNA agents Company 
Mimic miRNA microRNA  agomirs Accegen Biotechnology 
RGBiotech  
microUP™ miRNA agomir  Creative Biogene 
miRIDIAN microRNA mimics Dharmacon 
MISSION® miRNA mimics Merck (Previously Sigma-Aldrich) 
miScript miRNA mimics Qiagen (Previously Exiqon) 
miRNA mimics RGBiotech 
mirVana mimics Thermo Fisher Scientific 
Inhibit miRNA microRNA antagomirs Accegen Biotechnology 
RGBiotech 
microDOWN™ miRNA Creative Biogene 
miRIDIAN microRNA Hairpin     
inhibitors 
Dharmacon 
IDT® miRNA inhibitors Integrated DNA Technologies 
miScript miRNA inhibitors Qiagen (Previously Exiqon) 
miArrest miRNA inhibitors Genecopoeia 
miRNA Inhibitors RGBiotech 
mirVana miRNA inhibitors Thermo Fisher Scientific 
Ambion® anti-miR™ miRNA     
inhibitors 
Thermo Fisher Scientific 
MISSION® miRNA inhibitors Merck (Previously Sigma-Aldrich) 
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miRNA group 
effect 
MicroRNA sponge Accegen Biotechnology 
MicroRNA sponge Creative Biogene 
miRIDIAN microRNA mimic and 
inhibitor libraries 
Dharmacon 
miRCURY LNA power inhibitors Qiagen (Previously Exiqon) 
miRCURY LNA miRNA family 
power inhibitors 
Qiagen (Previously Exiqon) 
miRCURY LNA miRNA inhibitor 
libraries 
Qiagen (Previously Exiqon) 
miRNA expression clone RGBiotech 
miRNA mimic and inhibitor  
libraries 
Thermo Fisher Scientific 
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Table 2. Clinical medication and chemical agents present in diet can alter miRNA 
expression. * includes activated microglia or monocyte-derived macrophages 
Pathophysiology  MiRNA target Drug 
Cellular death Excitotoxicity miR-21 Metformin, bortezomib 
 Autophagy Let-7 
 
miR-25 
miR-155 
Epigallocatechin-3-O-gallate 
Panobinostat 
Isoliquiritigenin 
Natalizumab 
 Necrosis miR-21 
miR-155 
Metformin, bortezomib 
Natalizumab 
 Apoptosis miR-21 
miR-25 
miR-29 
Metformin, bortezomib 
Isoliquiritigenin 
Bleomycin, Imatinib 
Neuroinflammation Microglia Let-7 
 
miR-155 
Epigallocatechin-3-O-gallate 
Panobinostat 
Natalizumab 
 Astrocytes miR-7 
miR-21 
miR-29a, b 
miR-155 
Nicorandil  
Metformin, bortezomib 
Bleomycin, Imatinib 
Natalizumab 
 Macrophages* miR-21 
miR-155 
Metformin, bortezomib 
Natalizumab 
 Neutrophils miR-130a Curcumin 
 Dendritic cells miR-29b, c 
miR-155 
Bleomycin, Imatinib 
Natalizumab 
 T-lymphocytes miR-155 Natalizumab 
 B-lymphocytes miR-155 Natalizumab 
 
 
 
 
   29 
 
Acknowledgements:  
We would like to thank Barts Charity for their support of the Brain injury biomarkers in 
Newborns (BIBiNS) study.  
 
Declaration of Interest:  
None 
 
Funding Disclosure:  
This research did not receive any specific grant from funding agencies in the public, 
commercial, or not-for-profit sectors.  
 
 
  
   30 
References : 
 
 
1. Bartel, D.P., MicroRNAs: target recognition and regulatory functions. Cell, 2009. 
136(2): p. 215-33. 
2. Motti, D., J.L. Bixby, and V.P. Lemmon, MicroRNAs and neuronal development. Semin 
Fetal Neonatal Med, 2012. 17(6): p. 347-52. 
3. Sempere, L.F., et al., Expression profiling of mammalian microRNAs uncovers a subset of 
brain-expressed microRNAs with possible roles in murine and human neuronal differentiation. 
Genome Biol, 2004. 5(3): p. R13. 
4. Cheng, G., Circulating miRNAs: Roles in cancer diagnosis, prognosis and therapy. Adv 
Drug Deliv Rev, 2015. 81C: p. 75-93. 
5. Olson, E.N., MicroRNAs as therapeutic targets and biomarkers of cardiovascular disease. 
Sci Transl Med, 2014. 6(239): p. 239ps3. 
6. Biswas, S.K. and E. Lopez-Collazo, Endotoxin tolerance: new mechanisms, molecules and 
clinical significance. Trends Immunol, 2009. 30(10): p. 475-87. 
7. Grasso, M., et al., Circulating miRNAs as biomarkers for neurodegenerative disorders. 
Molecules, 2014. 19(5): p. 6891-910. 
8. Semple, B.D., et al., Brain development in rodents and humans: Identifying benchmarks of 
maturation and vulnerability to injury across species. Prog Neurobiol, 2013. 106-107: p. 1-16. 
9. Urban, N. and F. Guillemot, Neurogenesis in the embryonic and adult brain: same 
regulators, different roles. Front Cell Neurosci, 2014. 8: p. 396. 
10. Roese-Koerner, B., L. Stappert, and O. Brustle, Notch/Hes signaling and miR-9 engage in 
complex feedback interactions controlling neural progenitor cell proliferation and differentiation. 
Neurogenesis (Austin), 2017. 4(1): p. e1313647. 
11. Zhao, C., et al., MicroRNA <em>let-7b</em> regulates neural stem cell proliferation and 
differentiation by targeting nuclear receptor TLX signaling. Proceedings of the National Academy 
of Sciences, 2010. 107(5): p. 1876-1881. 
12. Romanko, M.J., R.P. Rothstein, and S.W. Levison, Neural stem cells in the subventricular 
zone are resilient to hypoxia/ischemia whereas progenitors are vulnerable. J Cereb Blood Flow 
Metab, 2004. 24(7): p. 814-25. 
13. Yang, Z. and S.W. Levison, Hypoxia/ischemia expands the regenerative capacity of 
progenitors in the perinatal subventricular zone. Neuroscience, 2006. 139(2): p. 555-64. 
14. Dizon, M., F. Szele, and J.A. Kessler, Hypoxia-ischemia induces an endogenous reparative 
response by local neural progenitors in the postnatal mouse telencephalon. Dev Neurosci, 2010. 
32(3): p. 173-83. 
15. Dugas, J.C., et al., Dicer1 and miR-219 Are Required for Normal Oligodendrocyte 
Differentiation and Myelination. Neuron, 2010. 65(5): p. 597-611. 
16. Zhao, X., et al., MicroRNA-mediated control of oligodendrocyte differentiation. Neuron, 
2010. 65(5): p. 612-26. 
17. Buono, K.D., et al., Mechanisms of mouse neural precursor expansion after neonatal 
hypoxia-ischemia. J Neurosci, 2015. 35(23): p. 8855-65. 
18. Birch, D., et al., MicroRNAs participate in the murine oligodendroglial response to perinatal 
hypoxia-ischemia. Pediatr Res, 2014. 76(4): p. 334-40. 
19. Zheng, K., et al., MicroRNAs are essential for the developmental switch from neurogenesis 
to gliogenesis in the developing spinal cord. J Neurosci, 2010. 30(24): p. 8245-50. 
20. Naka-Kaneda, H., et al., The miR-17/106-p38 axis is a key regulator of the neurogenic-to-
gliogenic transition in developing neural stem/progenitor cells. Proc Natl Acad Sci U S A, 2014. 
111(4): p. 1604-9. 
21. Coolen, M., S. Katz, and L. Bally-Cuif, miR-9: a versatile regulator of neurogenesis. Front 
Cell Neurosci, 2013. 7: p. 220. 
   31 
22. Aksoy-Aksel, A., F. Zampa, and G. Schratt, MicroRNAs and synaptic plasticity--a mutual 
relationship. Philos Trans R Soc Lond B Biol Sci, 2014. 369(1652). 
23. Follert, P., H. Cremer, and C. Beclin, MicroRNAs in brain development and function: a 
matter of flexibility and stability. Front Mol Neurosci, 2014. 7: p. 5. 
24. Ye, Y., et al., Role of MicroRNA in Governing Synaptic Plasticity. Neural Plast, 2016. 
2016: p. 4959523. 
25. Wei, C.W., et al., Research progress on the roles of microRNAs in governing synaptic 
plasticity, learning and memory. Life Sci, 2017. 188: p. 118-122. 
26. Lin, S.-T., et al., MicroRNA-23a promotes myelination in the central nervous system. 
Proceedings of the National Academy of Sciences of the United States of America, 2013. 110(43): 
p. 17468-17473. 
27. Abbott, N.J., et al., Structure and function of the blood-brain barrier. Neurobiol Dis, 2010. 
37(1): p. 13-25. 
28. Kalani, A., et al., Role of microRNA29b in blood–brain barrier dysfunction during 
hyperhomocysteinemia: an epigenetic mechanism. Journal of Cerebral Blood Flow & Metabolism, 
2014. 34(7): p. 1212-1222. 
29. Lagos-Quintana, M., et al., Identification of tissue-specific microRNAs from mouse. Curr 
Biol, 2002. 12(9): p. 735-9. 
30. Ason, B., et al., Differences in vertebrate microRNA expression. Proceedings of the National 
Academy of Sciences, 2006. 103(39): p. 14385-14389. 
31. Kapsimali, M., et al., MicroRNAs show a wide diversity of expression profiles in the 
developing and mature central nervous system. Genome Biol, 2007. 8(8): p. R173. 
32. Fabbri, M., et al., MicroRNAs bind to Toll-like receptors to induce prometastatic 
inflammatory response. Proceedings of the National Academy of Sciences of the United States of 
America, 2012. 109(31): p. E2110-E2116. 
33. Graham, E.M., et al., A systematic review of the role of intrapartum hypoxia-ischemia in the 
causation of neonatal encephalopathy. Am J Obstet Gynecol, 2008. 199(6): p. 587-95. 
34. Azzopardi, D., et al., The TOBY Study. Whole body hypothermia for the treatment of 
perinatal asphyxial encephalopathy: a randomised controlled trial. BMC Pediatr, 2008. 8: p. 17. 
35. Edwards, A.D., et al., Neurological outcomes at 18 months of age after moderate 
hypothermia for perinatal hypoxic ischaemic encephalopathy: synthesis and meta-analysis of trial 
data. The BMJ, 2010. 340: p. c363. 
36. Wintermark, P., Current Controversies in Newer Therapies to Treat Birth Asphyxia. 
International Journal of Pediatrics, 2011. 2011: p. 848413. 
37. Chen H, Y.T., Expression and significance of serum miRNA-21 control HIF-1a in newborn 
with asphyxia. Chinese J child health Care, 2015. 23: p. 32-34. 
38. Ponnusamy, V., et al., A study of microRNAs from dried blood spots in newborns after 
perinatal asphyxia: a simple and feasible biosampling method. Pediatr Res, 2016. 79(5): p. 799-805. 
39. Looney, A.M., et al., Downstream mRNA Target Analysis in Neonatal Hypoxic-Ischaemic 
Encephalopathy Identifies Novel Marker of Severe Injury: a Proof of Concept Paper. Mol 
Neurobiol, 2017. 54(10): p. 8420-8428. 
40. Looney, A.M., et al., Downregulation of Umbilical Cord Blood Levels of miR-374a in 
Neonatal Hypoxic Ischemic Encephalopathy. J Pediatr, 2015. 167(2): p. 269-73 e2. 
41. Wang, Z., et al., Combined prediction of miR-210 and miR-374a for severity and prognosis 
of hypoxic-ischemic encephalopathy. Brain Behav, 2018. 8(1): p. e00835. 
42. Whitehead, C.L., et al., Circulating MicroRNAs in Maternal Blood as Potential Biomarkers 
for Fetal Hypoxia In-Utero. PLoS ONE, 2013. 8(11): p. e78487. 
43. Cai, Q., et al., Protective mechanisms of microRNA-27a against oxygen-glucose 
deprivation-induced injuries in hippocampal neurons. Neural Regen Res, 2016. 11(8): p. 1285-92. 
44. Cao, Y.H., et al., A microRNA-152 that targets the phosphatase and tensin homolog to 
inhibit low oxygen induced-apoptosis in human brain microvascular endothelial cells. Genet Mol 
Res, 2016. 15(2). 
   32 
45. Qiu, J., et al., Neuroprotective Effects of MicroRNA-210 on Hypoxic-Ischemic 
Encephalopathy. BioMed Research International, 2013. 2013: p. 350419. 
46. Qu, Y., et al., MiR-139-5p inhibits HGTD-P and regulates neuronal apoptosis induced by 
hypoxia-ischemia in neonatal rats. Neurobiol Dis, 2014. 63: p. 184-93. 
47. Cui, H. and L. Yang, Analysis of microRNA expression detected by microarray of the 
cerebral cortex after hypoxic-ischemic brain injury. J Craniofac Surg, 2013. 24(6): p. 2147-52. 
48. Hua, Y.-J., et al., Identification and target prediction of miRNAs specifically expressed in 
rat neural tissue. BMC Genomics, 2009. 10: p. 214-214. 
49. Lingham I, A.-B.A., Martinello K, Meehan C, Tachtsidis I, Tann C, Hristova M, Fleiss B, 
Wolfs T, Kramer B, Klein N, Hagberg H, Gressens P, Robertson NJ, Serial microRNA 
measurements can differentiate hypoxia from infectionsensitised hypoxia in a piglet model of 
neonatal encephalopathy. 2017. 
50. Garberg, H.T., et al., Temporal Profile of Circulating microRNAs after Global Hypoxia-
Ischemia in Newborn Piglets. Neonatology, 2017. 111(2): p. 133-139. 
51. Truettner, J.S., et al., Therapeutic hypothermia alters microRNA responses to traumatic 
brain injury in rats. J Cereb Blood Flow Metab, 2011. 31(9): p. 1897-907. 
52. Allen, K.A. and D.H. Brandon, Hypoxic Ischemic Encephalopathy: Pathophysiology and 
Experimental Treatments. Newborn Infant Nurs Rev, 2011. 11(3): p. 125-133. 
53. Martin, L.J., et al., Neuronal death in newborn striatum after hypoxia-ischemia is necrosis 
and evolves with oxidative stress. Neurobiol Dis, 2000. 7(3): p. 169-91. 
54. Northington, F.J., R. Chavez-Valdez, and L.J. Martin, Neuronal cell death in neonatal 
hypoxia-ischemia. Ann Neurol, 2011. 69(5): p. 743-58. 
55. Zhang, B., et al., MicroRNA-23a Curbs Necrosis during Early T Cell Activation by 
Enforcing Intracellular Reactive Oxygen Species Equilibrium. Immunity, 2016. 44(3): p. 568-81. 
56. Wang, K., et al., miR-874 regulates myocardial necrosis by targeting caspase-8. Cell Death 
Dis, 2013. 4: p. e709. 
57. Wang, K., et al., MicroRNA-2861 regulates programmed necrosis in cardiomyocyte by 
impairing adenine nucleotide translocase 1 expression. Free Radic Biol Med, 2016. 91: p. 58-67. 
58. Rock, K.L. and H. Kono, The inflammatory response to cell death. Annu Rev Pathol, 2008. 
3: p. 99-126. 
59. Sato, A., et al., MicroRNA-351 Regulates Two-Types of Cell Death, Necrosis and 
Apoptosis, Induced by 5-fluoro-2'-deoxyuridine. PLoS ONE, 2016. 11(4): p. e0153130. 
60. Kroemer, G., et al., Classification of cell death: recommendations of the Nomenclature 
Committee on Cell Death 2009. Cell Death Differ, 2009. 16(1): p. 3-11. 
61. Kurosaka, K., et al., Silent cleanup of very early apoptotic cells by macrophages. J 
Immunol, 2003. 171(9): p. 4672-9. 
62. Jovanovic, M. and M.O. Hengartner, miRNAs and apoptosis: RNAs to die for. Oncogene, 
2006. 25(46): p. 6176-87. 
63. Wang, Y. and C.G. Lee, MicroRNA and cancer--focus on apoptosis. J Cell Mol Med, 2009. 
13(1): p. 12-23. 
64. Lima, R.T., et al., MicroRNA regulation of core apoptosis pathways in cancer. Eur J Cancer, 
2011. 47(2): p. 163-74. 
65. Su, Z., et al., MicroRNAs in apoptosis, autophagy and necroptosis. Oncotarget, 2015. 6(11): 
p. 8474-90. 
66. Fontana, L., et al., Antagomir-17-5p abolishes the growth of therapy-resistant 
neuroblastoma through p21 and BIM. PLoS One, 2008. 3(5): p. e2236. 
67. Bursch, W., The autophagosomal-lysosomal compartment in programmed cell death. Cell 
Death Differ, 2001. 8(6): p. 569-81. 
68. Gozuacik, D., et al., Autophagy-Regulating microRNAs and Cancer. Front Oncol, 2017. 7: 
p. 65. 
69. Dubinsky, A.N., et al., Let-7 coordinately suppresses components of the amino acid sensing 
pathway to repress mTORC1 and induce autophagy. Cell Metab, 2014. 20(4): p. 626-38. 
   33 
70. Wan, G., et al., Hypoxia-induced MIR155 is a potent autophagy inducer by targeting 
multiple players in the MTOR pathway. Autophagy, 2014. 10(1): p. 70-9. 
71. Xu, T.X., et al., Hypoxia responsive miR-210 promotes cell survival and autophagy of 
endometriotic cells in hypoxia. Eur Rev Med Pharmacol Sci, 2016. 20(3): p. 399-406. 
72. Portera-Cailliau, C., D.L. Price, and L.J. Martin, Excitotoxic neuronal death in the immature 
brain is an apoptosis-necrosis morphological continuum. J Comp Neurol, 1997. 378(1): p. 70-87. 
73. Harraz, M.M., et al., MicroRNA-223 is neuroprotective by targeting glutamate receptors. 
Proc Natl Acad Sci U S A, 2012. 109(46): p. 18962-7. 
74. Pocock, R. and O. Hobert, Oxygen levels affect axon guidance and neuronal migration in 
Caenorhabditis elegans. Nat Neurosci, 2008. 11(8): p. 894-900. 
75. Tekkok, S.B. and M.P. Goldberg, Ampa/kainate receptor activation mediates hypoxic 
oligodendrocyte death and axonal injury in cerebral white matter. J Neurosci, 2001. 21(12): p. 
4237-48. 
76. Viader, A., et al., MicroRNAs modulate Schwann cell response to nerve injury by 
reinforcing transcriptional silencing of dedifferentiation-related genes. J Neurosci, 2011. 31(48): p. 
17358-69. 
77. Ksiazek-Winiarek, D.J., M.J. Kacperska, and A. Glabinski, MicroRNAs as novel regulators 
of neuroinflammation. Mediators Inflamm, 2013. 2013: p. 172351. 
78. Brites, D. and A. Fernandes, Neuroinflammation and Depression: Microglia Activation, 
Extracellular Microvesicles and microRNA Dysregulation. Front Cell Neurosci, 2015. 9: p. 476. 
79. Ponomarev, E.D., T. Veremeyko, and H.L. Weiner, MicroRNAs are universal regulators of 
differentiation, activation, and polarization of microglia and macrophages in normal and diseased 
CNS. Glia, 2013. 61(1): p. 91-103. 
80. Jimenez, S., et al., Inflammatory response in the hippocampus of PS1M146L/APP751SL 
mouse model of Alzheimer's disease: age-dependent switch in the microglial phenotype from 
alternative to classic. J Neurosci, 2008. 28(45): p. 11650-61. 
81. Liu, F. and L.D. McCullough, Inflammatory responses in hypoxic ischemic encephalopathy. 
Acta Pharmacol Sin, 2013. 34(9): p. 1121-30. 
82. Cho, K.J., et al., MicroRNA-Let-7a regulates the function of microglia in inflammation. Mol 
Cell Neurosci, 2015. 68: p. 167-76. 
83. Ponomarev, E.D., et al., MicroRNA-124 promotes microglia quiescence and suppresses 
EAE by deactivating macrophages via the C/EBP-alpha-PU.1 pathway. Nat Med, 2011. 17(1): p. 
64-70. 
84. Langmann, T., et al., Loss of microRNA-124 and microRNA-126 expression regulates 
inflammatory microglial activation in inherited retinal degeneration. Investigative Opthalmology 
and Visual Science, 2013. 54(15): p. 4517-4517. 
85. Freilich, R.W., M.E. Woodbury, and T. Ikezu, Integrated expression profiles of mRNA and 
miRNA in polarized primary murine microglia. PLoS One, 2013. 8(11): p. e79416. 
86. Bowes, A.L. and P.K. Yip, Modulating inflammatory cell responses to spinal cord injury: all 
in good time. J Neurotrauma, 2014. 31(21): p. 1753-66. 
87. Colombo, E. and C. Farina, Astrocytes: Key Regulators of Neuroinflammation. Trends 
Immunol, 2016. 37(9): p. 608-620. 
88. Ouyang, Y.B., et al., Neuroprotection by astrocytes in brain ischemia: importance of 
microRNAs. Neurosci Lett, 2014. 565: p. 53-8. 
89. Rao, V.T., et al., MicroRNA Expression Patterns in Human Astrocytes in Relation to 
Anatomical Location and Age. J Neuropathol Exp Neurol, 2016. 75(2): p. 156-66. 
90. Dong, Y.F., et al., Potential role of microRNA-7 in the anti-neuroinflammation effects of 
nicorandil in astrocytes induced by oxygen-glucose deprivation. J Neuroinflammation, 2016. 13(1): 
p. 60. 
91. Ouyang, Y.B., et al., Astrocyte-enriched miR-29a targets PUMA and reduces neuronal 
vulnerability to forebrain ischemia. Glia, 2013. 61(11): p. 1784-94. 
   34 
92. Liu, L., et al., MicroRNA-34b mediates hippocampal astrocyte apoptosis in a rat model of 
recurrent seizures. BMC Neurosci, 2016. 17(1): p. 56. 
93. Tarassishin, L., et al., Interferon regulatory factor 3 inhibits astrocyte inflammatory gene 
expression through suppression of the proinflammatory miR-155 and miR-155*. Glia, 2011. 
59(12): p. 1911-22. 
94. Morel, L., et al., Neuronal exosomal miRNA-dependent translational regulation of astroglial 
glutamate transporter GLT1. J Biol Chem, 2013. 288(10): p. 7105-16. 
95. Gurol, T., W. Zhou, and Q. Deng, MicroRNAs in neutrophils: potential next generation 
therapeutics for inflammatory ailments. Immunol Rev, 2016. 273(1): p. 29-47. 
96. Ward, J.R., et al., Regulation of Neutrophil Senescence by MicroRNAs. PLoS ONE, 2011. 
6(1): p. e15810. 
97. Izumi, B., et al., MicroRNA-223 expression in neutrophils in the early phase of secondary 
damage after spinal cord injury. Neuroscience Letters, 2011. 492(2): p. 114-118. 
98. Bauernfeind, F., et al., NLRP3 inflammasome activity is negatively controlled by miR-223. 
J Immunol, 2012. 189(8): p. 4175-81. 
99. Li, M., D. Feng, and B. Gao, MicroRNA 223 ameliorates alcoholic liver injury in mice by 
suppressingneutrophil infiltration and functions. Gastroenterology, 2015. 148(4): p. S-976. 
100. Johnnidis, J.B., et al., Regulation of progenitor cell proliferation and granulocyte function 
by microRNA-223. Nature, 2008. 451(7182): p. 1125-9. 
101. Bazzoni, F., et al., Induction and regulatory function of miR-9 in human monocytes and 
neutrophils exposed to proinflammatory signals. Proceedings of the National Academy of Sciences, 
2009. 106(13): p. 5282-5287. 
102. Sheedy, F.J., et al., Negative regulation of TLR4 via targeting of the proinflammatory tumor 
suppressor PDCD4 by the microRNA miR-21. Nat Immunol, 2010. 11(2): p. 141-147. 
103. Barnett, R.E., et al., Anti-inflammatory effects of miR-21 in the macrophage response to 
peritonitis. J Leukoc Biol, 2016. 99(2): p. 361-71. 
104. Taganov, K.D., et al., NF-kappaB-dependent induction of microRNA miR-146, an inhibitor 
targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci U S A, 2006. 
103(33): p. 12481-6. 
105. Tili, E., et al., Modulation of miR-155 and miR-125b levels following 
lipopolysaccharide/TNF-alpha stimulation and their possible roles in regulating the response to 
endotoxin shock. J Immunol, 2007. 179(8): p. 5082-9. 
106. Bala, S., et al., Up-regulation of microRNA-155 in macrophages contributes to increased 
tumor necrosis factor {alpha} (TNF{alpha}) production via increased mRNA half-life in alcoholic 
liver disease. J Biol Chem, 2011. 286(2): p. 1436-44. 
107. O'Connell, R.M., et al., MicroRNA-155 is induced during the macrophage inflammatory 
response. Proc Natl Acad Sci U S A, 2007. 104(5): p. 1604-9. 
108. Androulidaki, A., et al., The kinase Akt1 controls macrophage response to 
lipopolysaccharide by regulating microRNAs. Immunity, 2009. 31(2): p. 220-31. 
109. Smyth, L.A., et al., MicroRNAs affect dendritic cell function and phenotype. Immunology, 
2015. 144(2): p. 197-205. 
110. Thai, T.H., et al., Regulation of the germinal center response by microRNA-155. Science, 
2007. 316(5824): p. 604-8. 
111. Kohlhaas, S., et al., Cutting edge: the Foxp3 target miR-155 contributes to the development 
of regulatory T cells. J Immunol, 2009. 182(5): p. 2578-82. 
112. Rodriguez, A., et al., Requirement of bic/microRNA-155 for normal immune function. 
Science, 2007. 316(5824): p. 608-11. 
113. Li, Q.J., et al., miR-181a is an intrinsic modulator of T cell sensitivity and selection. Cell, 
2007. 129(1): p. 147-61. 
114. Garcia, A.M., et al., T cell immunity in neonates. Immunol Res, 2000. 22(2-3): p. 177-90. 
115. Gibbons, D., et al., Interleukin-8 (CXCL8) production is a signatory T cell effector function 
of human newborn infants. Nat Med, 2014. 20(10): p. 1206-10. 
   35 
116. Kong, K.Y., et al., MIR-23A microRNA cluster inhibits B-cell development. Exp Hematol, 
2010. 38(8): p. 629-640.e1. 
117. Rao, D.S., et al., MicroRNA-34a perturbs B lymphocyte development by repressing the 
forkhead box transcription factor Foxp1. Immunity, 2010. 33(1): p. 48-59. 
118. Mehta, A., et al., The microRNA-212/132 cluster regulates B cell development by targeting 
Sox4. The Journal of Experimental Medicine, 2015. 212(10): p. 1679. 
119. Vigorito, E., et al., microRNA-155 regulates the generation of immunoglobulin class-
switched plasma cells. Immunity, 2007. 27(6): p. 847-59. 
120. Chen, C.Z., et al., MicroRNAs modulate hematopoietic lineage differentiation. Science, 
2004. 303(5654): p. 83-6. 
121. de Yebenes, V.G., et al., miR-181b negatively regulates activation-induced cytidine 
deaminase in B cells. J Exp Med, 2008. 205(10): p. 2199-206. 
122. Kim, J. and M. Yenari, Hypothermia for treatment of Stroke. Brain Circulation, 2015. 1(1): 
p. 14-25. 
123. Andersson, P., et al., Plasma levels of liver-specific miR-122 is massively increased in a 
porcine cardiogenic shock model and attenuated by hypothermia. Shock, 2012. 37(2): p. 234-8. 
124. Billeter, A.T., et al., MicroRNA-155 potentiates the inflammatory response in hypothermia 
by suppressing IL-10 production. Faseb j, 2014. 28(12): p. 5322-36. 
125. Dresios, J., et al., Cold stress-induced protein Rbm3 binds 60S ribosomal subunits, alters 
microRNA levels, and enhances global protein synthesis. Proc Natl Acad Sci U S A, 2005. 102(6): 
p. 1865-70. 
126. Mayr, F., et al., The Lin28 cold-shock domain remodels pre-let-7 microRNA. Nucleic Acids 
Res, 2012. 40(15): p. 7492-506. 
127. Shankaran, S., Neonatal Encephalopathy: Treatment with Hypothermia. Journal of 
Neurotrauma, 2009. 26(3): p. 437-443. 
128. Lam, J.K., et al., siRNA Versus miRNA as Therapeutics for Gene Silencing. Mol Ther 
Nucleic Acids, 2015. 4: p. e252. 
129. Diaz Quiroz, J.F., et al., Precise control of miR-125b levels is required to create a 
regeneration-permissive environment after spinal cord injury: a cross-species comparison between 
salamander and rat. Dis Model Mech, 2014. 7(6): p. 601-11. 
130. Willemen, H.L., et al., MicroRNA-124 as a novel treatment for persistent hyperalgesia. J 
Neuroinflammation, 2012. 9: p. 143. 
131. Cao, H., et al., A new plasmid-based microRNA inhibitor system that inhibits microRNA 
families in transgenic mice and cells: a potential new therapeutic reagent. Gene Ther, 2016. 23(6): 
p. 527-42. 
132. Haraguchi, T., Y. Ozaki, and H. Iba, Vectors expressing efficient RNA decoys achieve the 
long-term suppression of specific microRNA activity in mammalian cells. Nucleic Acids Res, 2009. 
37(6): p. e43. 
133. Ye, Y., et al., Downregulation of microRNA-29 by antisense inhibitors and a PPAR-gamma 
agonist protects against myocardial ischaemia-reperfusion injury. Cardiovasc Res, 2010. 87(3): p. 
535-44. 
134. Maurer, B., et al., MicroRNA-29, a key regulator of collagen expression in systemic 
sclerosis. Arthritis Rheum, 2010. 62(6): p. 1733-43. 
135. Chen, X., et al., Oncogenic miR-9 is a target of erlotinib in NSCLCs. Sci Rep, 2015. 5: p. 
17031. 
136. Oikawa, H., et al., Valproic acid mediates miR-124 to down-regulate a novel protein target, 
GNAI1. Neurochem Int, 2015. 91: p. 62-71. 
137. Mameli, G., et al., Natalizumab Therapy Modulates miR-155, miR-26a and 
Proinflammatory Cytokine Expression in MS Patients. PLoS One, 2016. 11(6): p. e0157153. 
138. Luo, M., et al., MiRNA-21 mediates the antiangiogenic activity of metformin through 
targeting PTEN and SMAD7 expression and PI3K/AKT pathway. Sci Rep, 2017. 7: p. 43427. 
   36 
139. Zhu, H., et al., MicroRNA-21 in scleroderma fibrosis and its function in TGF-beta-regulated 
fibrosis-related genes expression. J Clin Immunol, 2013. 33(6): p. 1100-9. 
140. Di Fazio, P., et al., Downregulation of HMGA2 by the pan-deacetylase inhibitor 
panobinostat is dependent on hsa-let-7b expression in liver cancer cell lines. Exp Cell Res, 2012. 
318(15): p. 1832-43. 
141. Dou, H., et al., Curcumin Suppresses the Colon Cancer Proliferation by Inhibiting Wnt/beta-
Catenin Pathways via miR-130a. Front Pharmacol, 2017. 8: p. 877. 
142. Yamada, S., et al., Epigallocatechin-3-O-gallate up-regulates microRNA-let-7b expression 
by activating 67-kDa laminin receptor signaling in melanoma cells. Sci Rep, 2016. 6: p. 19225. 
143. Wang, Z., et al., MicroRNA-25 regulates chemoresistance-associated autophagy in breast 
cancer cells, a process modulated by the natural autophagy inducer isoliquiritigenin. Oncotarget, 
2014. 5(16): p. 7013-26. 
144. Krek, A., et al., Combinatorial microRNA target predictions. Nat Genet, 2005. 37(5): p. 
495-500. 
145. Cherry, J.D., J.A. Olschowka, and M.K. O'Banion, Neuroinflammation and M2 microglia: 
the good, the bad, and the inflamed. J Neuroinflammation, 2014. 11: p. 98. 
146. Kielian, T., Neuroinflammation: good, bad, or indifferent? J Neurochem, 2014. 130(1): p. 1-
3. 
147. Sun, E. and Y. Shi, MicroRNAs: Small molecules with big roles in neurodevelopment and 
diseases. Exp Neurol, 2015. 268: p. 46-53. 
148. Yokoi, T. and M. Nakajima, Toxicological implications of modulation of gene expression 
by microRNAs. Toxicol Sci, 2011. 123(1): p. 1-14. 
149. Tsuchiya, Y., et al., MicroRNA regulates the expression of human cytochrome P450 1B1. 
Cancer Res, 2006. 66(18): p. 9090-8. 
150. Delaloy, C., et al., MicroRNA-9 coordinates proliferation and migration of human 
embryonic stem cell-derived neural progenitors. Cell Stem Cell, 2010. 6(4): p. 323-35. 
151. Brett, J.O., et al., The microRNA cluster miR-106b~25 regulates adult neural 
stem/progenitor cell proliferation and neuronal differentiation. Aging (Albany NY), 2011. 3(2): p. 
108-24. 
152. Gaughwin, P., et al., Stage-specific modulation of cortical neuronal development by Mmu-
miR-134. Cereb Cortex, 2011. 21(8): p. 1857-69. 
153. Sun, G., et al., miR-137 forms a regulatory loop with nuclear receptor TLX and LSD1 in 
neural stem cells. Nature Communications, 2011. 2: p. 529-529. 
154. Liu, C., et al., Epigenetic regulation of miR-184 by MBD1 governs neural stem cell 
proliferation and differentiation. Cell stem cell, 2010. 6(5): p. 433-444. 
155. Zhao, C., et al., MicroRNA let-7b regulates neural stem cell proliferation and differentiation 
by targeting nuclear receptor TLX signaling. Proc Natl Acad Sci U S A, 2010. 107(5): p. 1876-81. 
156. Nishino, J., et al., Hmga2 promotes neural stem cell self-renewal in young but not old mice 
by reducing p16Ink4a and p19Arf Expression. Cell, 2008. 135(2): p. 227-39. 
157. Zhang, W., et al., MiRNA-128 regulates the proliferation and neurogenesis of neural 
precursors by targeting PCM1 in the developing cortex. Elife, 2016. 5. 
158. Wang, Y., et al., MicroRNA-506-3p regulates neural stem cell proliferation and 
differentiation through targeting TCF3. Gene, 2016. 593(1): p. 193-200. 
159. Zhao, C., et al., A feedback regulatory loop involving microRNA-9 and nuclear receptor 
TLX in neural stem cell fate determination. Nature structural & molecular biology, 2009. 16(4): p. 
365-371. 
160. Dill, H., et al., Intronic miR-26b controls neuronal differentiation by repressing its host 
transcript, ctdsp2. Genes Dev, 2012. 26(1): p. 25-30. 
161. Aranha, M.M., et al., miR-34a regulates mouse neural stem cell differentiation. PLoS One, 
2011. 6(8): p. e21396. 
162. Cheng, L.C., et al., miR-124 regulates adult neurogenesis in the subventricular zone stem 
cell niche. Nat Neurosci, 2009. 12(4): p. 399-408. 
   37 
163. Makeyev, E.V., et al., The MicroRNA miR-124 promotes neuronal differentiation by 
triggering brain-specific alternative pre-mRNA splicing. Mol Cell, 2007. 27(3): p. 435-48. 
164. Le, M.T.N., et al., MicroRNA-125b Promotes Neuronal Differentiation in Human Cells by 
Repressing Multiple Targets. Molecular and Cellular Biology, 2009. 29(19): p. 5290-5305. 
165. Morgado, A.L., C.M. Rodrigues, and S. Sola, MicroRNA-145 Regulates Neural Stem Cell 
Differentiation Through the Sox2-Lin28/let-7 Signaling Pathway. Stem Cells, 2016. 34(5): p. 1386-
95. 
166. Smrt, R.D., et al., MicroRNA miR-137 regulates neuronal maturation by targeting ubiquitin 
ligase mind bomb-1. Stem Cells, 2010. 28(6): p. 1060-70. 
167. Baek, S.T., et al., Off-target effect of doublecortin family shRNA on neuronal migration 
associated with endogenous microRNA dysregulation. Neuron, 2014. 82(6): p. 1255-1262. 
168. Kos, A., et al., MicroRNA-338 modulates cortical neuronal placement and polarity. RNA 
Biol, 2017. 14(7): p. 905-913. 
169. Rago, L., et al., miR379-410 cluster miRNAs regulate neurogenesis and neuronal migration 
by fine-tuning N-cadherin. Embo j, 2014. 33(8): p. 906-20. 
170. Volvert, M.L., et al., MicroRNA targeting of CoREST controls polarization of migrating 
cortical neurons. Cell Rep, 2014. 7(4): p. 1168-83. 
171. Franzoni, E., et al., miR-128 regulates neuronal migration, outgrowth and intrinsic 
excitability via the intellectual disability gene Phf6. Elife, 2015. 4. 
172. Wang, Y., et al., Epithelial microRNA-9a regulates dendrite growth through Fmi-Gq 
signaling in Drosophila sensory neurons. Dev Neurobiol, 2016. 76(2): p. 225-37. 
173. Xue, Q., et al., miR-9 and miR-124 synergistically affect regulation of dendritic branching 
via the AKT/GSK3beta pathway by targeting Rap2a. Sci Rep, 2016. 6: p. 26781. 
174. Giusti, S.A., et al., MicroRNA-9 controls dendritic development by targeting REST. Elife, 
2014. 3. 
175. Li, B. and H. Sun, MiR-26a promotes neurite outgrowth by repressing PTEN expression. 
Mol Med Rep, 2013. 8(2): p. 676-80. 
176. Jiang, J.J., et al., MicroRNA-26a supports mammalian axon regeneration in vivo by 
suppressing GSK3beta expression. Cell Death Dis, 2015. 6: p. e1865. 
177. Li, H., et al., MicroRNA-29a modulates axon branching by targeting doublecortin in 
primary neurons. Protein Cell, 2014. 5(2): p. 160-9. 
178. Tan, C., et al., Expression of MicroRNA-29a Regulated by Yes-Associated Protein 
Modulates the Neurite Outgrowth in N2a Cells %J BioMed Research International. 2017. 2017: p. 
13. 
179. Gu, X., et al., CBX2 Inhibits Neurite Development by Regulating Neuron-Specific Genes 
Expression. Frontiers in Molecular Neuroscience, 2018. 11: p. 46. 
180. Vo, N., et al., A cAMP-response element binding protein-induced microRNA regulates 
neuronal morphogenesis. Proc Natl Acad Sci U S A, 2005. 102(45): p. 16426-31. 
181. Lu, X.C., et al., MiR-133b Promotes neurite outgrowth by targeting RhoA expression. Cell 
Physiol Biochem, 2015. 35(1): p. 246-58. 
182. Magill, S.T., et al., microRNA-132 regulates dendritic growth and arborization of newborn 
neurons in the adult hippocampus. Proc Natl Acad Sci U S A, 2010. 107(47): p. 20382-7. 
183. Irie, K., et al., MicroRNA-214 Promotes Dendritic Development by Targeting the 
Schizophrenia-associated Gene Quaking (Qki). The Journal of Biological Chemistry, 2016. 
291(26): p. 13891-13904. 
184. He, Q.-Q., et al., MicroRNA-127 targeting of mitoNEET inhibits neurite outgrowth, induces 
cell apoptosis and contributes to physiological dysfunction after spinal cord transection. Scientific 
Reports, 2016. 6: p. 35205. 
185. Schratt, G.M., et al., A brain-specific microRNA regulates dendritic spine development. 
Nature, 2006. 439(7074): p. 283-9. 
   38 
186. Siegel, G., et al., A functional screen implicates microRNA-138-dependent regulation of the 
depalmitoylation enzyme APT1 in dendritic spine morphogenesis. Nat Cell Biol, 2009. 11(6): p. 
705-16. 
187. Harraz, M.M., et al., MiR-223 regulates the differentiation of immature neurons. Molecular 
and cellular therapies, 2014. 2: p. 18. 
188. Dajas-Bailador, F., et al., microRNA-9 regulates axon extension and branching by targeting 
Map1b in mouse cortical neurons. Nat Neurosci, 2012. 
189. Zhang, Y., et al., The MicroRNA-17-92 cluster enhances axonal outgrowth in embryonic 
cortical neurons. J Neurosci, 2013. 33(16): p. 6885-94. 
190. Han, F., et al., MicroRNA-30b promotes axon outgrowth of retinal ganglion cells by 
inhibiting Semaphorin3A expression. Brain Res, 2015. 1611: p. 65-73. 
191. Wu, D. and A.K. Murashov, MicroRNA-431 regulates axon regeneration in mature sensory 
neurons by targeting the Wnt antagonist Kremen1. Frontiers in Molecular Neuroscience, 2013. 6: p. 
35. 
192. Basu, A., et al., &lt;em&gt;let-7&lt;/em&gt; miRNA controls CED-7 homotypic adhesion 
and EFF-1–mediated axonal self-fusion to restore touch sensation following injury. Proceedings of 
the National Academy of Sciences, 2017. 114(47): p. E10206. 
193. Kar, A.N., et al., Intra-axonal Synthesis of Eukaryotic Translation Initiation Factors 
Regulate Local Protein Synthesis and Axon Growth in Rat Sympathetic Neurons. The Journal of 
neuroscience : the official journal of the Society for Neuroscience, 2013. 33(17): p. 7165-7174. 
194. Kos, A., et al., MicroRNA-181 promotes synaptogenesis and attenuates axonal outgrowth in 
cortical neurons. Cell Mol Life Sci, 2016. 73(18): p. 3555-67. 
195. Aschrafi, A., et al., MicroRNA-338 regulates the axonal expression of multiple nuclear-
encoded mitochondrial mRNAs encoding subunits of the oxidative phosphorylation machinery. Cell 
Mol Life Sci, 2012. 69(23): p. 4017-27. 
196. Sim, S.E., et al., The Brain-Enriched MicroRNA miR-9-3p Regulates Synaptic Plasticity 
and Memory. J Neurosci, 2016. 36(33): p. 8641-52. 
197. Schumacher, S. and K. Franke, miR-124-regulated RhoG: A conductor of neuronal process 
complexity. Small GTPases, 2013. 4(1): p. 42-6. 
198. Muddashetty, R.S., et al., Reversible inhibition of PSD-95 mRNA translation by miR-125a, 
FMRP phosphorylation, and mGluR signaling. Mol Cell, 2011. 42(5): p. 673-88. 
199. Lee, K., et al., An activity-regulated microRNA, miR-188, controls dendritic plasticity and 
synaptic transmission by downregulating neuropilin-2. J Neurosci, 2012. 32(16): p. 5678-5687. 
200. Fiumara, F., et al., MicroRNA-22 Gates Long-Term Heterosynaptic Plasticity in Aplysia 
through Presynaptic Regulation of CPEB and Downstream Targets. Cell Rep, 2015. 11(12): p. 
1866-75. 
201. Wang, X., et al., A Novel MicroRNA-124/PTPN1 Signal Pathway Mediates Synaptic and 
Memory Deficits in Alzheimer's Disease. Biol Psychiatry, 2018. 83(5): p. 395-405. 
202. Banzhaf-Strathmann, J., et al., MicroRNA-125b induces tau hyperphosphorylation and 
cognitive deficits in Alzheimer's disease. Embo j, 2014. 33(15): p. 1667-80. 
203. Schroder, J., et al., MicroRNA-138 is a potential regulator of memory performance in 
humans. Front Hum Neurosci, 2014. 8: p. 501. 
204. Saba, R., et al., Dopamine-regulated microRNA MiR-181a controls GluA2 surface 
expression in hippocampal neurons. Mol Cell Biol, 2012. 32(3): p. 619-32. 
205. Capitano, F., et al., MicroRNA-335-5p modulates spatial memory and hippocampal synaptic 
plasticity. Neurobiol Learn Mem, 2017. 139: p. 63-68. 
206. Cohen, J.E., et al., MicroRNA regulation of homeostatic synaptic plasticity. Proc Natl Acad 
Sci U S A, 2011. 108(28): p. 11650-5. 
207. Patterson, M., et al., let-7 miRNAs Can Act through Notch to Regulate Human Gliogenesis. 
Stem Cell Reports, 2014. 3(5): p. 758-773. 
208. Zhao, X., et al., Specification and maintenance of oligodendrocyte precursor cells from 
neural progenitor cells: involvement of microRNA-7a. Mol Biol Cell, 2012. 23(15): p. 2867-78. 
   39 
209. Budde, H., et al., Control of oligodendroglial cell number by the miR-17-92 cluster. 
Development, 2010. 137(13): p. 2127-32. 
210. Gioia, U., et al., Mir-23a and mir-125b regulate neural stem/progenitor cell proliferation by 
targeting Musashi1. RNA Biol, 2014. 11(9): p. 1105-12. 
211. Santra, M., et al., Thymosin beta4 up-regulation of microRNA-146a promotes 
oligodendrocyte differentiation and suppression of the Toll-like proinflammatory pathway. J Biol 
Chem, 2014. 289(28): p. 19508-18. 
212. Kuypers, N.J., et al., Remyelinating Oligodendrocyte Precursor Cell miRNAs from the 
Sfmbt2 Cluster Promote Cell Cycle Arrest and Differentiation. J Neurosci, 2016. 36(5): p. 1698-
710. 
213. Bian, S., et al., MicroRNA cluster miR-17-92 regulates neural stem cell expansion and 
transition to intermediate progenitors in the developing mouse neocortex. Cell Rep, 2013. 3(5): p. 
1398-1406. 
214. Akerblom, M., et al., MicroRNA-124 is a subventricular zone neuronal fate determinant. J 
Neurosci, 2012. 32(26): p. 8879-89. 
215. Letzen, B.S., et al., MicroRNA expression profiling of oligodendrocyte differentiation from 
human embryonic stem cells. PLoS One, 2010. 5(5): p. e10480. 
216. Tsuyama, J., et al., MicroRNA-153 Regulates the Acquisition of Gliogenic Competence by 
Neural Stem Cells. Stem Cell Reports, 2015. 5(3): p. 365-77. 
217. Wang, H., et al., miR-219 Cooperates with miR-338 in Myelination and Promotes Myelin 
Repair in the CNS. Dev Cell, 2017. 40(6): p. 566-582.e5. 
218. Kuehbacher, A., et al., Role of Dicer and Drosha for endothelial microRNA expression and 
angiogenesis. Circ Res, 2007. 101(1): p. 59-68. 
219. Madelaine, R., et al., microRNA-9 couples brain neurogenesis and angiogenesis. Cell 
reports, 2017. 20(7): p. 1533-1542. 
220. Chen, Y. and D.H. Gorski, Regulation of angiogenesis through a microRNA (miR-130a) 
that down-regulates antiangiogenic homeobox genes GAX and HOXA5. Blood, 2008. 111(3): p. 
1217-26. 
221. Zeng, L., et al., MicroRNA-210 overexpression induces angiogenesis and neurogenesis in 
the normal adult mouse brain. Gene Ther, 2014. 21(1): p. 37-43. 
222. Yin, K.J., et al., Vascular endothelial cell-specific microRNA-15a inhibits angiogenesis in 
hindlimb ischemia. J Biol Chem, 2012. 287(32): p. 27055-64. 
223. Chen, F., et al., Up-regulation of microRNA-16 in Glioblastoma Inhibits the Function of 
Endothelial Cells and Tumor Angiogenesis by Targeting Bmi-1. Anticancer Agents Med Chem, 
2016. 16(5): p. 609-20. 
224. Shi, Z.M., et al., MiR-128 inhibits tumor growth and angiogenesis by targeting p70S6K1. 
PLoS One, 2012. 7(3): p. e32709. 
225. Zhao, W.-J., H.-F. Zhang, and J.-Y. Su, Downregulation of microRNA-195 promotes 
angiogenesis induced by cerebral infarction via targeting VEGFA. Molecular Medicine Reports, 
2017. 16(4): p. 5434-5440. 
226. Suarez, Y., et al., Dicer dependent microRNAs regulate gene expression and functions in 
human endothelial cells. Circ Res, 2007. 100(8): p. 1164-73. 
227. Kalani, A., et al., Role of microRNA29b in blood-brain barrier dysfunction during 
hyperhomocysteinemia: an epigenetic mechanism. J Cereb Blood Flow Metab, 2014. 34(7): p. 
1212-22. 
228. Liu, W., et al., MicroRNA-107 prevents amyloid-beta induced blood-brain barrier disruption 
and endothelial cell dysfunction by targeting Endophilin-1. Exp Cell Res, 2016. 343(2): p. 248-257. 
229. Reijerkerk, A., et al., MicroRNAs regulate human brain endothelial cell-barrier function in 
inflammation: implications for multiple sclerosis. J Neurosci, 2013. 33(16): p. 6857-63. 
230. Lalwani, M.K., et al., Reverse genetics screen in zebrafish identifies a role of miR-142a-3p 
in vascular development and integrity. PLoS One, 2012. 7(12): p. e52588. 
   40 
231. Li, D., et al., miR-285–Yki/Mask double-negative feedback loop mediates blood–brain 
barrier integrity in Drosophila. Proceedings of the National Academy of Sciences of the United 
States of America, 2017. 114(12): p. E2365-E2374. 
232. Xi, T., et al., MicroRNA-126-3p attenuates blood-brain barrier disruption, cerebral edema 
and neuronal injury following intracerebral hemorrhage by regulating PIK3R2 and Akt. Biochem 
Biophys Res Commun, 2017. 494(1-2): p. 144-151. 
233. Bai, Y., et al., Silencing microRNA-143 protects the integrity of the blood-brain barrier: 
implications for methamphetamine abuse. Sci Rep, 2016. 6: p. 35642. 
234. Fang, Z., et al., MicroRNA-150 regulates blood-brain barrier permeability via Tie-2 after 
permanent middle cerebral artery occlusion in rats. Faseb j, 2016. 30(6): p. 2097-107. 
235. Lopez-Ramirez, M.A., et al., MicroRNA-155 negatively affects blood-brain barrier function 
during neuroinflammation. Faseb j, 2014. 28(6): p. 2551-65. 
236. Ma, Q., et al., MicroRNA-210 Suppresses Junction Proteins and Disrupts Blood-Brain 
Barrier Integrity in Neonatal Rat Hypoxic-Ischemic Brain Injury. Int J Mol Sci, 2017. 18(7). 
237. Naim, N., et al. Experimental analysis of potential micrornas encoded during and after blood 
brain barrier disruption. in Proceedings of the 6th International Symposium on Health Informatics 
and Bioinformatics. 2011. 
238. Yildirim, S.S., et al., Relationship between downregulation of miRNAs and increase of 
oxidative stress in the development of diabetic cardiac dysfunction: junctin as a target protein of 
miR-1. Cell Biochem Biophys, 2013. 67(3): p. 1397-408. 
239. Corbel, C., et al., Developmental attenuation of N-methyl-D-aspartate receptor subunit 
expression by microRNAs. Neural Development, 2015. 10(1): p. 20. 
240. Yelamanchili, S.V., et al., MicroRNA-21 dysregulates the expression of MEF2C in neurons 
in monkey and human SIV/HIV neurological disease. Cell Death Dis, 2010. 1: p. e77. 
241. Tan, C.L., et al., MicroRNA-128 governs neuronal excitability and motor behavior in mice. 
Science (New York, N.Y.), 2013. 342(6163): p. 1254-1258. 
242. Boese, A., et al., MicroRNA-128 and microRNA-342-3p's Roles in Excitotoxicity Related 
Neuronal Death During Prion Induced Neurodegeneration. Vol. 5. 2011. 30-31. 
243. Guerau-de-Arellano, M., et al., Analysis of miRNA in Normal Appearing White Matter to 
Identify Altered CNS Pathways in Multiple Sclerosis. J Autoimmune Disord, 2015. 1(1). 
244. Zhang, Y., et al., α-Melanocyte-stimulating hormone prevents glutamate excitotoxicity in 
developing chicken retina via MC4R-mediated down-regulation of microRNA-194. Scientific 
Reports, 2015. 5: p. 15812. 
245. Stary, C.M., et al., MicroRNA-200c contributes to injury from transient focal cerebral 
ischemia by targeting Reelin. Stroke, 2015. 46(2): p. 551-6. 
246. Verma, P., et al., A neuroprotective role for microRNA miR-1000 mediated by limiting 
glutamate excitotoxicity. Nature Neuroscience, 2015. 18: p. 379. 
247. Sun, K.T., et al., MicroRNA-20a regulates autophagy related protein-ATG16L1 in hypoxia-
induced osteoclast differentiation. Bone, 2015. 73: p. 145-53. 
248. Yu, Y., et al., Targeting microRNA-30a-mediated autophagy enhances imatinib activity 
against human chronic myeloid leukemia cells. Leukemia, 2012. 26(8): p. 1752-60. 
249. Zou, Z., et al., MicroRNA-30a sensitizes tumor cells to cis-platinum via suppressing beclin 
1-mediated autophagy. J Biol Chem, 2012. 287(6): p. 4148-56. 
250. Liao, H., et al., microRNA-32 induces radioresistance by targeting DAB2IP and regulating 
autophagy in prostate cancer cells. Oncol Lett, 2015. 10(4): p. 2055-2062. 
251. Morgado, A.L., et al., MicroRNA-34a Modulates Neural Stem Cell Differentiation by 
Regulating Expression of Synaptic and Autophagic Proteins. Mol Neurobiol, 2015. 51(3): p. 1168-
83. 
252. Liu, X.J., et al., MicroRNA-34a Suppresses Autophagy in Tubular Epithelial Cells in Acute 
Kidney Injury. Am J Nephrol, 2015. 42(2): p. 168-75. 
253. Ge, Y.Y., et al., MicroRNA-100 promotes the autophagy of hepatocellular carcinoma cells 
by inhibiting the expression of mTOR and IGF-1R. Oncotarget, 2014. 5(15): p. 6218-28. 
   41 
254. Frankel, L.B., et al., microRNA-101 is a potent inhibitor of autophagy. Embo j, 2011. 
30(22): p. 4628-41. 
255. Kim, J.K., et al., MicroRNA-125a Inhibits Autophagy Activation and Antimicrobial 
Responses during Mycobacterial Infection. J Immunol, 2015. 194(11): p. 5355-65. 
256. Higashi, K., et al., MicroRNA-145 repairs infarcted myocardium by accelerating 
cardiomyocyte autophagy. Am J Physiol Heart Circ Physiol, 2015. 309(11): p. H1813-26. 
257. Zhang, F., et al., MicroRNA-146a Induced by Hypoxia Promotes Chondrocyte Autophagy 
through Bcl-2. Cell Physiol Biochem, 2015. 37(4): p. 1442-53. 
258. Wang, J., et al., MicroRNA-155 promotes autophagy to eliminate intracellular mycobacteria 
by targeting Rheb. PLoS Pathog, 2013. 9(10): p. e1003697. 
259. Wu, K., et al., MicroRNA-155-enhanced autophagy in human gastric epithelial cell in 
response to Helicobacter pylori. Saudi J Gastroenterol, 2016. 22(1): p. 30-6. 
260. D'Adamo, S., et al., MicroRNA-155 suppresses autophagy in chondrocytes by modulating 
expression of autophagy proteins. Osteoarthritis Cartilage, 2016. 24(6): p. 1082-91. 
261. Mo, J., D. Zhang, and R. Yang, MicroRNA-195 regulates proliferation, migration, 
angiogenesis and autophagy of endothelial progenitor cells by targeting GABARAPL1. Bioscience 
Reports, 2016. 36(5): p. e00396. 
262. Xiao, J., et al., MiR-204 regulates cardiomyocyte autophagy induced by ischemia-
reperfusion through LC3-II. Journal of Biomedical Science, 2011. 18(1): p. 35-35. 
263. Jianfeng, X., et al., GW24-e2431 MicroRNA-210 Over-expression Activates Autophagy in 
Mesenchymal Stem Cells and Improves its Therapeutic Effect on the Myocardial Infarction: an 
<em>in vitro</em> and <em>in vivo</em> Study. Heart, 2013. 99(Suppl 3): p. A108-A108. 
264. Su, M., et al., MicroRNA-221 inhibits autophagy and promotes heart failure by modulating 
the p27/CDK2/mTOR axis. Cell Death Differ, 2015. 22(6): p. 986-99. 
265. Li, W., et al., MicroRNA-495 regulates starvation-induced autophagy by targeting ATG3. 
FEBS Lett, 2016. 590(6): p. 726-38. 
266. Hu, M.X., et al., Functional role of MicroRNA-19b in acinar cell necrosis in acute 
necrotizing pancreatitis. J Huazhong Univ Sci Technolog Med Sci, 2016. 36(2): p. 221-225. 
267. Ma, X., et al., The oncogenic microRNA miR-21 promotes regulated necrosis in mice. Nat 
Commun, 2015. 6: p. 7151. 
268. Sharifi, M., et al., Inhibition of microRNA miR-92a induces apoptosis and necrosis in 
human acute promyelocytic leukemia. Advanced Biomedical Research, 2014. 3: p. 61. 
269. Dhingra, R., J. Lin, and L.A. Kirshenbaum, Disruption of RIP1-FADD Complexes by 
MicroRNA-103/107 Provokes Necrotic Cardiac Cell Death. Circ Res, 2015. 117(4): p. 314-6. 
270. Liu, J., et al., MicroRNA-155 prevents necrotic cell death in human cardiomyocyte 
progenitor cells via targeting RIP1. J Cell Mol Med, 2011. 15(7): p. 1474-82. 
271. Hu, J.Z., et al., Anti-apoptotic effect of microRNA-21 after contusion spinal cord injury in 
rats. J Neurotrauma, 2013. 30(15): p. 1349-60. 
272. Chan, J.A., A.M. Krichevsky, and K.S. Kosik, MicroRNA-21 is an antiapoptotic factor in 
human glioblastoma cells. Cancer Res, 2005. 65(14): p. 6029-33. 
273. Nolan, K., et al., Endoplasmic reticulum stress-mediated upregulation of miR-29a enhances 
sensitivity to neuronal apoptosis. Eur J Neurosci, 2016. 43(5): p. 640-52. 
274. Welch, C., Y. Chen, and R.L. Stallings, MicroRNA-34a functions as a potential tumor 
suppressor by inducing apoptosis in neuroblastoma cells. Oncogene, 2007. 26(34): p. 5017-22. 
275. Ma, Q.Q., et al., MicroRNA-96 Regulates Apoptosis by Targeting PDCD4 in Human 
Glioma Cells. Technol Cancer Res Treat, 2017. 16(1): p. 92-98. 
276. Kong, N., X. Lu, and B. Li, Downregulation of microRNA-100 protects apoptosis and 
promotes neuronal growth in retinal ganglion cells. BMC Mol Biol, 2014. 15: p. 25. 
277. Liu, X., et al., MicroRNA-124-mediated regulation of inhibitory member of apoptosis-
stimulating protein of p53 family in experimental stroke. Stroke, 2013. 44(7): p. 1973-80. 
278. Zhang, S., et al., MicroRNA-210 regulates cell proliferation and apoptosis by targeting 
regulator of differentiation 1 in glioblastoma cells. Folia Neuropathol, 2015. 53(3): p. 236-44. 
   42 
279. Creevey, L., et al., MicroRNA-497 increases apoptosis in MYCN amplified neuroblastoma 
cells by targeting the key cell cycle regulator WEE1. Mol Cancer, 2013. 12: p. 23. 
280. Wu, C.D., et al., MicroRNA-1 induces apoptosis by targeting prothymosin alpha in 
nasopharyngeal carcinoma cells. J Biomed Sci, 2011. 18: p. 80. 
281. Zhu, K., et al., MicroRNA-15a Inhibits Proliferation and Induces Apoptosis in CNE1 
Nasopharyngeal Carcinoma Cells. Oncol Res, 2016. 24(3): p. 145-51. 
282. Xiong, Y., et al., Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of 
hepatocellular carcinoma. Hepatology, 2010. 51(3): p. 836-45. 
283. Mott, J.L., et al., mir-29 regulates Mcl-1 protein expression and apoptosis. Oncogene, 2007. 
26(42): p. 6133-40. 
284. Chang, T.C., et al., Transactivation of miR-34a by p53 broadly influences gene expression 
and promotes apoptosis. Mol Cell, 2007. 26(5): p. 745-52. 
285. Ji, Q., et al., Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric 
cancer tumorspheres. BMC Cancer, 2008. 8: p. 266. 
286. Esau, C., et al., miR-122 regulation of lipid metabolism revealed by in vivo antisense 
targeting. Cell Metab, 2006. 3(2): p. 87-98. 
287. Lin, C.J., et al., miR-122 targets an anti-apoptotic gene, Bcl-w, in human hepatocellular 
carcinoma cell lines. Biochem Biophys Res Commun, 2008. 375(3): p. 315-20. 
288. Li, C., et al., Hepatitis B virus mRNA-mediated miR-122 inhibition upregulates PTTG1-
binding protein, which promotes hepatocellular carcinoma tumor growth and cell invasion. J Virol, 
2013. 87(4): p. 2193-205. 
289. Chen, Y., et al., miR-122 targets NOD2 to decrease intestinal epithelial cell injury in 
Crohn's disease. Biochem Biophys Res Commun, 2013. 438(1): p. 133-9. 
290. MacKenzie, T.N., et al., Triptolide Induces the Expression of miR-142-3p: a Negative 
Regulator of Heat Shock Protein 70 and Pancreatic Cancer Cell Proliferation. Molecular cancer 
therapeutics, 2013. 12(7): p. 1266-1275. 
291. Gironella, M., et al., Tumor protein 53-induced nuclear protein 1 expression is repressed by 
miR-155, and its restoration inhibits pancreatic tumor development. Proc Natl Acad Sci U S A, 
2007. 104(41): p. 16170-5. 
292. Liu, L., et al., microRNA-195 promotes apoptosis and suppresses tumorigenicity of human 
colorectal cancer cells. Biochem Biophys Res Commun, 2010. 400(2): p. 236-40. 
293. Chun-Zhi, Z., et al., MicroRNA-221 and microRNA-222 regulate gastric carcinoma cell 
proliferation and radioresistance by targeting PTEN. BMC Cancer, 2010. 10: p. 367. 
294. Wang, Y., et al., Profiling microRNA expression in hepatocellular carcinoma reveals 
microRNA-224 up-regulation and apoptosis inhibitor-5 as a microRNA-224-specific target. J Biol 
Chem, 2008. 283(19): p. 13205-15. 
295. Wu, N., et al., CRCT1 regulated by microRNA-520 g inhibits proliferation and induces 
apoptosis in esophageal squamous cell cancer. Tumour Biol, 2016. 37(6): p. 8271-9. 
296. Zhang, Y., G. Talmon, and J. Wang, MicroRNA-587 antagonizes 5-FU-induced apoptosis 
and confers drug resistance by regulating PPP2R1B expression in colorectal cancer. Cell Death Dis, 
2015. 6: p. e1845. 
297. Lee, Y.E., et al., MicroRNA-1 participates in nitric oxide-induced apoptotic insults to 
MC3T3-E1 cells by targeting heat-shock protein-70. Int J Biol Sci, 2015. 11(3): p. 246-55. 
298. Guo, L., et al., MicroRNA-17-92a upregulation by estrogen leads to Bim targeting and 
inhibition of osteoblast apoptosis. J Cell Sci, 2013. 126(Pt 4): p. 978-88. 
299. Baumhoer, D., et al., MicroRNA profiling with correlation to gene expression revealed the 
oncogenic miR-17-92 cluster to be up-regulated in osteosarcoma. Cancer Genet, 2012. 205(5): p. 
212-9. 
300. Zhang, W., et al., The microRNA-29 plays a central role in osteosarcoma pathogenesis and 
progression. Mol Biol (Mosk), 2012. 46(4): p. 622-7. 
301. Tian, Y., Y.Z. Zhang, and W. Chen, MicroRNA-199a-3p and microRNA-34a regulate 
apoptosis in human osteosarcoma cells. Biosci Rep, 2014. 34(4). 
   43 
302. Niederer, F., et al., Down-regulation of microRNA-34a* in rheumatoid arthritis synovial 
fibroblasts promotes apoptosis resistance. Arthritis Rheum, 2012. 64(6): p. 1771-9. 
303. He, C., et al., Functional elucidation of MiR-34 in osteosarcoma cells and primary tumor 
samples. Biochem Biophys Res Commun, 2009. 388(1): p. 35-40. 
304. Bai, R., et al., MicroRNA-195 induced apoptosis in hypoxic chondrocytes by targeting 
hypoxia-inducible factor 1 alpha. Eur Rev Med Pharmacol Sci, 2015. 19(4): p. 545-51. 
305. Li, G., et al., Heat shock protein 90B1 plays an oncogenic role and is a target of microRNA-
223 in human osteosarcoma. Cell Physiol Biochem, 2012. 30(6): p. 1481-90. 
306. Zhou, C., et al., Hypoxia-inducible microRNA-488 regulates apoptosis by targeting Bim in 
osteosarcoma. Cell Oncol (Dordr), 2016. 39(5): p. 463-471. 
307. Huang, J., et al., microRNA miR-10b inhibition reduces cell proliferation and promotes 
apoptosis in non-small cell lung cancer (NSCLC) cells. Mol Biosyst, 2015. 11(7): p. 2051-9. 
308. Matsubara, H., et al., Apoptosis induction by antisense oligonucleotides against miR-17-5p 
and miR-20a in lung cancers overexpressing miR-17-92. Oncogene, 2007. 26(41): p. 6099-105. 
309. Chen, Z., et al., Elevated microRNA-25 inhibits cell apoptosis in lung cancer by targeting 
RGS3. In Vitro Cell Dev Biol Anim, 2016. 52(1): p. 62-7. 
310. Bommer, G.T., et al., p53-mediated activation of miRNA34 candidate tumor-suppressor 
genes. Curr Biol, 2007. 17(15): p. 1298-307. 
311. Tanaka, N., et al., Frequent methylation and oncogenic role of microRNA-34b/c in small-
cell lung cancer. Lung Cancer, 2012. 76(1): p. 32-8. 
312. Le, M.T., et al., MicroRNA-125b is a novel negative regulator of p53. Genes Dev, 2009. 
23(7): p. 862-76. 
313. Joshi, P., et al., MicroRNA-148a reduces tumorigenesis and increases TRAIL-induced 
apoptosis in NSCLC. Proc Natl Acad Sci U S A, 2015. 112(28): p. 8650-5. 
314. Garofalo, M., et al., MicroRNA signatures of TRAIL resistance in human non-small cell 
lung cancer. Oncogene, 2008. 27(27): p. 3845-55. 
315. Pan, Z., et al., miR-1 exacerbates cardiac ischemia-reperfusion injury in mouse models. 
PLoS One, 2012. 7(11): p. e50515. 
316. Tang, Y., et al., MicroRNA-1 regulates cardiomyocyte apoptosis by targeting Bcl-2. Int 
Heart J, 2009. 50(3): p. 377-87. 
317. Gallego, I., et al., Potential role of microRNA-10b down-regulation in cardiomyocyte 
apoptosis in aortic stenosis patients. Clin Sci (Lond), 2016. 130(23): p. 2139-2149. 
318. Liu, L., et al., MicroRNA-15b enhances hypoxia/reoxygenation-induced apoptosis of 
cardiomyocytes via a mitochondrial apoptotic pathway. Apoptosis, 2014. 19(1): p. 19-29. 
319. Du, W., et al., By targeting Stat3 microRNA-17-5p promotes cardiomyocyte apoptosis in 
response to ischemia followed by reperfusion. Cell Physiol Biochem, 2014. 34(3): p. 955-65. 
320. Song, S., et al., MicroRNA-17-mediated down-regulation of apoptotic protease activating 
factor 1 attenuates apoptosome formation and subsequent apoptosis of cardiomyocytes. Biochem 
Biophys Res Commun, 2015. 465(2): p. 299-304. 
321. Sayed, D., et al., MicroRNA-21 Is a Downstream Effector of AKT That Mediates Its 
Antiapoptotic Effects via Suppression of Fas Ligand. The Journal of Biological Chemistry, 2010. 
285(26): p. 20281-20290. 
322. Cheng, Y., et al., MicroRNA-21 protects against the H(2)O(2)-induced injury on cardiac 
myocytes via its target gene PDCD4. J Mol Cell Cardiol, 2009. 47(1): p. 5-14. 
323. Fan, F., et al., MicroRNA-34a promotes cardiomyocyte apoptosis post myocardial infarction 
through down-regulating aldehyde dehydrogenase 2. Curr Pharm Des, 2013. 19(27): p. 4865-73. 
324. Rane, S., et al., Downregulation of miR-199a derepresses hypoxia-inducible factor-1alpha 
and Sirtuin 1 and recapitulates hypoxia preconditioning in cardiac myocytes. Circ Res, 2009. 
104(7): p. 879-86. 
325. Huang, Y., et al., MicroRNA-208a Potentiates Angiotensin II-triggered Cardiac Myoblasts 
Apoptosis via Inhibiting Nemo-like Kinase (NLK). Curr Pharm Des, 2016. 22(31): p. 4868-4875. 
   44 
326. Ren, X.P., et al., MicroRNA-320 is involved in the regulation of cardiac 
ischemia/reperfusion injury by targeting heat-shock protein 20. Circulation, 2009. 119(17): p. 2357-
2366. 
327. Zhu, X.D., et al., MicroRNA-377 Mediates Cardiomyocyte Apoptosis Induced by 
Cyclosporin A. Can J Cardiol, 2016. 32(10): p. 1249-1259. 
328. Parisi, C., et al., MicroRNA-125b regulates microglia activation and motor neuron death in 
ALS. Cell Death Differ, 2016. 23(3): p. 531-41. 
329. Akerblom, M., et al., microRNA-125 distinguishes developmentally generated and adult-
born olfactory bulb interneurons. Development, 2014. 141(7): p. 1580-8. 
330. Thome, A.D., et al., microRNA-155 Regulates Alpha-Synuclein-Induced Inflammatory 
Responses in Models of Parkinson Disease. J Neurosci, 2016. 36(8): p. 2383-90. 
331. Thounaojam, M.C., et al., MicroRNA 155 regulates Japanese encephalitis virus-induced 
inflammatory response by targeting Src homology 2-containing inositol phosphatase 1. J Virol, 
2014. 88(9): p. 4798-810. 
332. Yan, H., et al., Upregulation of miRNA-155 expression by OxLDL in dendritic cells 
involves JAK1/2 kinase and transcription factors YY1 and MYB. Int J Mol Med, 2016. 37(5): p. 
1371-8. 
333. Zhang, L., et al., The microRNA miR-181c controls microglia-mediated neuronal apoptosis 
by suppressing tumor necrosis factor. J Neuroinflammation, 2012. 9: p. 211. 
334. Jadhav, S.P., et al., microRNA-200b modulates microglia-mediated neuroinflammation via 
the cJun/MAPK pathway. J Neurochem, 2014. 130(3): p. 388-401. 
335. Zhao, H., et al., MiRNA-424 protects against permanent focal cerebral ischemia injury in 
mice involving suppressing microglia activation. Stroke, 2013. 44(6): p. 1706-13. 
336. Zhao, J., et al., Ngn1 inhibits astrogliogenesis through induction of miR-9 during neuronal 
fate specification. Elife, 2015. 4: p. e06885. 
337. Bhalala, O.G., et al., microRNA-21 regulates astrocytic response following spinal cord 
injury. J Neurosci, 2012. 32(50): p. 17935-47. 
338. Neo, W.H., et al., MicroRNA miR-124 controls the choice between neuronal and astrocyte 
differentiation by fine-tuning Ezh2 expression. J Biol Chem, 2014. 289(30): p. 20788-801. 
339. Wang, C.Y., S.H. Yang, and S.F. Tzeng, MicroRNA-145 as one negative regulator of 
astrogliosis. Glia, 2015. 63(2): p. 194-205. 
340. Iyer, A., et al., MicroRNA-146a: a key regulator of astrocyte-mediated inflammatory 
response. PLoS One, 2012. 7(9): p. e44789. 
341. Shu, M., et al., MicroRNA 335 is required for differentiation of malignant glioma cells 
induced by activation of cAMP/protein kinase A pathway. Mol Pharmacol, 2012. 81(3): p. 292-8. 
342. Gilicze, A.B., et al., Myeloid-derived microRNAs, miR-223, miR27a, and miR-652, are 
dominant players in myeloid regulation. Biomed Res Int, 2014. 2014: p. 870267. 
343. Surmiak, M., et al., Neutrophil MiRNA-128-3p is Decreased During Active Phase of 
Granulo-matosis with Polyangiitis. Current Genomics, 2015. 16(5): p. 359-365. 
344. Pedersen, C.C., et al., Impact of microRNA-130a on the neutrophil proteome. BMC 
Immunology, 2015. 16(1): p. 70. 
345. Tanaka, K., et al., MiR-142 Is Required for Staphylococcus aureus Clearance at Skin 
Wound Sites via Small GTPase-Mediated Regulation of the Neutrophil Actin Cytoskeleton. J Invest 
Dermatol, 2017. 137(4): p. 931-940. 
346. Li, M., et al., MicroRNA-223 ameliorates alcoholic liver injury by inhibiting the IL-6-
p47phox-oxidative stress pathway in neutrophils. Gut, 2016. 
347. Murata, K., et al., MicroRNA-451 down-regulates neutrophil chemotaxis via p38 MAPK. 
Arthritis Rheumatol, 2014. 66(3): p. 549-59. 
348. Wei, T., et al., MicroRNA 486-3P as a stability marker in acute coronary syndrome. Biosci 
Rep, 2016. 36(3). 
349. Ward, P.A., The bipolar role of miR-466l in inflammation. Immunity, 2013. 39(5): p. 801-2. 
   45 
350. Kim, S.J., P.K. Gregersen, and B. Diamond, Regulation of dendritic cell activation by 
microRNA let-7c and BLIMP1. J Clin Invest, 2013. 123(2): p. 823-33. 
351. Sun, Y., et al., MicroRNA let-7i regulates dendritic cells maturation targeting interleukin-10 
via the Janus kinase 1-signal transducer and activator of transcription 3 signal pathway 
subsequently induces prolonged cardiac allograft survival in rats. J Heart Lung Transplant, 2016. 
35(3): p. 378-88. 
352. Liang, X., et al., MicroRNA-22 impairs anti-tumor ability of dendritic cells by targeting 
p38. PLoS One, 2015. 10(3): p. e0121510. 
353. Huang, A., et al., MiR-34a promotes DCs development and inhibits their function on T cell 
activation by targeting WNT1. Oncotarget, 2017. 8(10): p. 17191-17201. 
354. Sun, Y., et al., Targeting of microRNA-142-3p in dendritic cells regulates endotoxin-
induced mortality. Blood, 2011. 117(23): p. 6172-6183. 
355. Du, J., et al., Aberrant elevated microRNA-146a in dendritic cells (DC) induced by human 
pancreatic cancer cell line BxPC-3-conditioned medium inhibits DC maturation and activation. 
Med Oncol, 2012. 29(4): p. 2814-23. 
356. Dueck, A., et al., A miR-155-dependent microRNA hierarchy in dendritic cell maturation 
and macrophage activation. FEBS Lett, 2014. 588(4): p. 632-40. 
357. Wang, J., et al., microRNA-155 deficiency impairs dendritic cell function in breast cancer. 
Oncoimmunology, 2016. 5(11): p. e1232223. 
358. Ceppi, M., et al., MicroRNA-155 modulates the interleukin-1 signaling pathway in activated 
human monocyte-derived dendritic cells. Proc Natl Acad Sci U S A, 2009. 106(8): p. 2735-40. 
359. Roensch, K., MiRNA-155 regulates IL-12 expression by targeting SOCS-1 in human 
dendritic cells. 2010. 
360. Wu, C., et al., microRNA-181a represses ox-LDL-stimulated inflammatory response in 
dendritic cell by targeting c-Fos. Journal of Lipid Research, 2012. 53(11): p. 2355-2363. 
361. Zhou, H., et al., MicroRNA-223 Regulates the Differentiation and Function of Intestinal 
Dendritic Cells and Macrophages by Targeting C/EBPbeta. Cell Rep, 2015. 13(6): p. 1149-60. 
362. Talebi, F., et al., MicroRNA-142 regulates inflammation and T cell differentiation in an 
animal model of multiple sclerosis. J Neuroinflammation, 2017. 14(1): p. 55. 
363. Lu, L.F., et al., Function of miR-146a in controlling Treg cell-mediated regulation of Th1 
responses. Cell, 2010. 142(6): p. 914-29. 
364. Krebs, C.F., et al., MicroRNA-155 drives TH17 immune response and tissue injury in 
experimental crescentic GN. J Am Soc Nephrol, 2013. 24(12): p. 1955-65. 
365. Kurkewich, J.L., et al., The mirn23a microRNA cluster antagonizes B cell development. J 
Leukoc Biol, 2016. 100(4): p. 665-677. 
366. Gonzalez-Martin, A., et al., The microRNA miR-148a functions as a critical regulator of B 
cell tolerance and autoimmunity. Nat Immunol, 2016. 17(4): p. 433-40. 
367. Nakagawa, R., et al., MicroRNA-155 controls affinity-based selection by protecting c-
MYC+ B cells from apoptosis. J Clin Invest, 2016. 126(1): p. 377-88. 
368. Cui, B., et al., MicroRNA-155 influences B-cell receptor signaling and associates with 
aggressive disease in chronic lymphocytic leukemia. Blood, 2014. 124(4): p. 546-54. 
369. Luo, S., et al., The role of microRNA-1246 in the regulation of B cell activation and the 
pathogenesis of systemic lupus erythematosus. Clinical Epigenetics, 2015. 7(1): p. 24. 
 
